UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K
(Mark One)
|X| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended March 31, 2004
OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Transition period from ____________ to ____________
Commission file number 000-22673
SCHICK TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 11-3374812
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
30-00 47th Avenue, Long Island City, NY 11101
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (718) 937-5765
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common stock, par value $.01 per share
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes |X| No |_|
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. |_|
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2).
Yes |_| No |X|
The aggregate market value of Common Stock held by non-affiliates of the
registrant as of September 30, 2003, the last business day of the registrant's
most recently completed second fiscal quarter, was approximately $57,888,985.
Such aggregate market value is computed by reference to the closing sale price
of the Common Stock on such date.
As of June 10, 2004, the number of shares outstanding of the Registrant's
Common Stock, par value $.01 per share, was 15,028,793
DOCUMENTS INCORPORATED BY REFERENCE:
NONE
Table of Contents
Item of Form 10-K Page
Part I
Item 1. Business ................................................................................. 1
Item 2. Properties ............................................................................... 11
Item 3. Legal Proceedings ........................................................................ 11
Item 4. Submission of Matters to a Vote of Security Holders ...................................... 12
Part II
Item 5. Market for the Registrant's Common Equity and Related Stockholder Matters ................ 12
Item 6. Selected Financial Data .................................................................. 14
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations .... 15
Item 7A. Quantitative and Qualitative Disclosures About Market Risk ............................... 22
Item 8. Financial Statements and Supplementary Data .............................................. 22
Item 9. Changes in and Disagreements with Accountants On Accounting and Financial Disclosure ..... 22
Item 9A. Controls and Procedures .................................................................. 22
Part III
Item 10. Directors and Executive Officers of the Registrant ....................................... 22
Item 11. Executive Compensation ................................................................... 27
Item 12. Security Ownership of Certain Beneficial Owners And Management ........................... 31
Item 13. Certain Relationships and Related Transactions ........................................... 34
Item 14. Principal Accountant Fees and Services ................................................... 34
Part IV
Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K ......................... F-1
FORWARD-LOOKING STATEMENTS
This Form 10-K Annual Report contains forward-looking statements that
involve risk and uncertainties. All statements, other than statements of
historical facts, included in this Annual Report regarding the Company, its
financial position, products, business strategy and plans and objectives of
management of the Company for future operations, are forward-looking statements.
When used in this Annual Report, words such as "anticipate," "believe,"
"estimate," "expect," "intend," "objectives," "plans" and similar expressions,
or the negatives thereof or variations thereon or comparable terminology as they
relate to the Company, its products or its management, identify forward-looking
statements. Such forward-looking statements are based on the beliefs of the
Company's management, as well as assumptions made by and information currently
available to the Company's management. Actual results could differ materially
from those contemplated by the forward-looking statements as a result of various
factors, including, but not limited to, those contained in "Management's
Discussion and Analysis of Financial Condition and Results of Operations" in
this Annual Report and the "Risk Factors" set forth in Exhibit 99.1 to this
Annual Report. All subsequent written and oral forward-looking statements
attributable to the Company or persons acting on its behalf are expressly
qualified in their entirety by this paragraph.
PART I
ITEM 1. BUSINESS
Schick Technologies, Inc. (the "Company") designs, develops and
manufactures innovative digital radiographic imaging systems and devices, which
are based on proprietary digital imaging technologies, for the dental and
medical markets.
In the field of dentistry, the Company offers an integrated filmless
solution for the dental professional. The Company's major products include:
(i) the CDR(R) (computed dental radiography) imaging system;
(ii) Dental Imaging Software;
(iii) CDR Wireless(TM);
(iv) USBCam(TM);
(v) CDRPan(R); and
(vi) CDRPanX(TM).
The CDR(R) system, which has become a leading product in the field over
the past decade, uses an intra-oral sensor to produce instant, full size,
high-resolution dental x-ray images on a color computer monitor without the use
of film or the need for chemical development. Additionally, CDR(R) dramatically
reduces the radiation dose to which a patient may be exposed -- by up to 80% as
compared with conventional x-ray film. CDR Wireless(TM), introduced in February
2003, is an innovative wireless instant digital dental x-ray system that
combines all of the advantages of digital radiography with greater flexibility
and ease of placement. The USBCam(TM), the first intra-oral dental camera to
provide full motion video via a standard USB port, was introduced by the Company
in July 2002. It fully integrates with the CDR(R) system and eliminates the need
for camera power supplies and video capture cards. CDRPan(R), sold since
September 1999, eliminates the need for x-ray film in panoramic dental
diagnostic procedures and can be easily retrofitted onto existing panoramic
dental x-ray machines. CDRPanX(TM) introduced by the Company in November 2003,
is an integrated digital panoramic device, which allows for fully digital
panoramic dental diagnostic procedures.
In addition, the Company is developing other products and devices for the
dental field, as well as updated versions of its current products.
1
In the field of medical radiography, the Company manufactures and sells
the accuDEXA(R) bone densitometer, a low-cost and easy-to-operate device for the
assessment of bone mineral density and fracture risk.
The Company's core products are based primarily on its proprietary
active-pixel sensor ("APS") imaging technology. In addition, certain of the
Company's products are based upon its proprietary enhanced
charged-coupled-device ("CCD") imaging technology. APS allows the fabrication of
large-area imaging devices with high resolution at a fraction of the cost of
traditional technologies. APS technology, developed by the California Institute
of Technology and initially licensed to Photobit Corporation, is licensed to
Micron Technology, Inc.; it is sublicensed to the Company for a broad range of
health care applications.
The Company's objective is to be the leading provider of innovative, high
resolution, cost effective digital radiography products. The Company plans to
leverage its technological advantage in the digital imaging field to penetrate a
broad range of diagnostic imaging markets. The Company believes that its
proprietary technologies and expertise in electronics, imaging software and
advanced packaging may enable it to compete successfully in these markets. Key
elements of the Company's strategy include (i) expanding market leadership in
dental digital radiography; (ii) enhancing the Company's international
distribution channels; and (iii) broadening the Company's product offerings.
The Company's business was founded in 1992 and it was incorporated in
Delaware in 1997. On July 7, 1997, the Company completed an initial public
offering of its Common Stock. Proceeds to the Company after expenses of the
offering were approximately $33,508,000.
Under generally accepted accounting principles, the Company operates in
one reportable segment: digital radiographic imaging systems. Note 1 to the
Company's Consolidated Financial Statements summarizes, by percentage, the
Company's revenues from its principal products.
The Company's offices are located at 30-00 47th Avenue, Long Island City,
New York 11101. The Company's telephone number is (718) 937-5765, and its
website address is http://www.schicktech.com.
PRODUCTS / INDUSTRY
Digital Imaging
X-ray imaging, or radiography, is widely used as a basic diagnostic
technique in a broad range of medical applications. To produce a conventional
radiograph, a film cassette is placed behind the anatomy to be imaged. A
generator, which produces high-energy photons known as x-rays, is positioned
opposite the film cassette. The transmitted x-rays pass through soft tissue,
such as skin and muscle, and are absorbed by harder substances, such as bone.
These x-rays then form a latent image upon the film. After exposure, the film is
passed through a series of chemicals and then dried.
Film, however, has certain inherent limitations, including the time,
operating expense, inconvenience and uncertainty associated with film
processing, as well as the cost of disposal of waste chemicals and the need for
compliance with environmental regulations. Furthermore, the radiation dosage
levels required to assure adequate image quality in conventional film may raise
concerns regarding the health risks associated with exposure to radiation. Also,
conventional film images cannot be electronically retrieved from patient records
or electronically transmitted to health care providers or insurance carriers at
remote locations, a capability which has become increasingly important in
today's managed care environment. While certain x-ray scanning systems can
convert x-rays into digital form, they add to the time and expense associated
with the use of conventional film and do not eliminate the drawbacks of film
processing.
2
Digital radiography products have been developed to overcome the
limitations of conventional film. These systems replace the conventional film
cassette with an electronic receptor which directly converts the incident x-rays
to digital images.
Dental Imaging
In contrast to physicians, who often operate within highly-specialized
fields, dentists typically perform their own radiology work. They utilize a
significant volume of radiographic products and operate a substantial quantity
of radiographic equipment. The Company believes that there is a potential market
for approximately 1.1 million digital dental radiography devices worldwide.
According to the American Dental Association, there are approximately 150,000
practicing dentists in the United States. The Company believes that each of
them, on average, operates 2.5 radiological units, creating a potential market
of 375,000 digital dental radiography devices in the United States. In addition,
the Company believes that there are approximately 600,000 practicing dentists in
the world's major healthcare markets outside of the United States and that each
of them, on average, operates 1.25 radiological units, creating a potential
market of 750,000 additional devices. According to a survey of United States
dentists, reported in Dental Products Report in November 2003, the market
penetration for digital dental radiography devices among the survey respondents
was 17.1%.
The Company believes that dentists have a particularly strong motivation
to adopt digital radiography. Radiographic examinations are an integral part of
routine dental checkups and the dentist is directly involved in the film
development process. The use of digital radiography eliminates delays in film
processing, thus increasing the dentist's potential revenue stream and
efficiency, and reduces overhead expenses. The use of digital radiography also
allows dentists to more effectively communicate diagnoses and treatment plans to
patients and to easily store and display patients' previous dental x-ray images,
which the Company believes have the potential to increase the rate of patients'
treatment acceptance and resulting revenues. Finally, the radiation dosage
required to produce an intra-oral dental x-ray, which is high when compared with
other medical radiographs, can be reduced by up to 80% through the use of
digital radiography.
The Company's principal revenue-generating product is its CDR(R) computed
dental radiography imaging system. The Company's CDR(R) system is easy to
operate and can be used with any dental x-ray generator. To produce a digital
x-ray image using CDR(R), the dentist selects an intra-oral sensor of suitable
size and places it in the patient's mouth. The sensor converts the x-rays into a
digital image that is displayed on the computer monitor within five seconds and
automatically stored as part of the patient's clinical records. CDR(R) system
software allows the dentist to perform a variety of advanced diagnostic
operations on the image. The sensor can then be repositioned for the next x-ray.
As the x-ray dose is significantly lower than that required for conventional
x-ray film, concern over the potential health risk posed by multiple x-ray
exposures is greatly diminished. The process is easy and intuitive, enabling
nearly any member of the dental staff to operate the CDR(R) system with minimal
training.
The Company manufactures wired digital sensors in three sizes which
correspond to the three standard sizes of conventional dental x-ray film. Size 0
nominally measures 31 x 22.5 x 5.3mm and is designed for pediatric use; size 1
nominally measures 37.7 x 25 x 5.3mm and is designed for taking anterior dental
images; and size 2 nominally measures 43.5 x 30.6 x 5.3mm and is designed for
taking bitewing images. All of the Company's CDR(R) sensors can be disinfected
using cold solutions or gas. The typical CDR(R) configuration includes a
computer, display monitor, size 2 digital sensor, imaging software and a USB
remote module.
In February 2003, the Company announced the introduction of CDR
Wireless(TM), which the Company believes to have been the world's first wireless
instant dental x-ray system. It allows dentists to produce high-quality instant
radiographs with low radiation dosage and without the need for a cable between
the intra-oral sensor and computer. The Company currently manufactures Size 1
and Size 2 wireless sensors.
3
The Size 1 sensor nominally measures 37.7 x 25 x 6.6mm and the Size 2 sensor
nominally measures 43.5 x 30.6 x 5.3mm.
The Company began selling its intra-oral camera, the CDRCam(R), in early
1997 and a redesigned version, the CDRCam 2000, in November 1999. In April 2002,
the Company introduced the USBCam(TM), an innovative intra-oral camera which
fully integrates with the CDR(R) system to provide color video images of the
structures of the mouth. The Company believes that the USBCam(TM) was the
world's first intra-oral camera with a direct USB interface. Since their
introduction in 1991, intra-oral cameras have become widely accepted in
dentistry as a diagnostic, communication and presentation tool.
In March 1999, the Company commenced the sale of its digital panoramic
imaging device, the CDRPan(R). This device, which is designed to be retrofitted
into conventional panoramic dental x-ray machines, replaces film with electronic
sensors and a computer. This obviates the need for film and provides
instantaneous images, thus offering substantial savings in terms of time and
costs. Additionally, the CDRPan(R) easily integrates with practice management
and other computer software applications. An integrated digital panoramic
machine, marketed under the CDRPanX(TM) name, was introduced by the Company in
November 2003. It is a stand-alone device that performs digital panoramic
imaging for use in dentistry and maxillofacial surgery. The CDRPanX(TM) is
currently sold abroad; the Company plans to introduce this product to the U.S.
market during fiscal 2005.
Bone Mineral Density / Fracture Risk Assessment
Assessment of bone mineral density ("BMD") is an essential component in
the diagnosis and monitoring of osteoporosis. Osteoporosis is a disease that
causes progressive loss of bone mass which, in serious cases, may result in bone
fractures and even death. Until recently, osteoporosis was considered neither
treatable nor preventable. Because recognized treatments are now available and
because osteoporosis may be preventable if detected in its early stages, the
demand for BMD diagnostic equipment has significantly increased. The Company's
accuDEXA(R) device is an innovative BMD assessment device used to assist doctors
in the diagnosis of low bone density and prediction of fracture risk. The
Company believes that this low-cost and precise diagnostic tool assesses BMD
more quickly and easily than any comparable product currently on the market,
while using a minimal radiation dosage. It is a point-of-treatment tool,
designed for use by primary care physicians as part of a patient's physical
examination where indicated. In December 1997, the Company received clearance
from the United States Food and Drug Administration ("FDA") for marketing the
accuDEXA(R) as a BMD assessment device; in June, 1998 and May 2000, the FDA
granted the Company additional clearances for its marketing of the accuDEXA(R),
respectively, as a predictor of fracture risk and to further clarify issues
regarding the collection of the normative database.
Based on APS technology, accuDEXA(R) is a small self-contained unit
capable of instantly assessing the BMD of a specific portion of the patient's
hand, a relative indicator of BMD elsewhere in the body. This device is the
first BMD assessment instrument that is virtually automatic, requiring little
operator intervention or interfacing other than the entry of relevant patient
data into a built-in touch sensitive LCD screen. The device requires no external
x-ray generator or computer and it exposes the patient to less than 1% of the
radiation of a single conventional chest x-ray. To perform a test using the
accuDEXA(R), the patient places his or her hand into position and, upon
activation by the operator, the device automatically emits two low-dosage x-ray
pulses. The patient's bone density and fracture risk information is displayed on
the screen in less than 30 seconds.
MANUFACTURING
The Company's manufacturing facility is located at its headquarters in
Long Island City, New York. This facility is subject to periodic inspection by
the FDA. The Company assembles its CDR(R) sensors, CDRPan(R) and CDRPanX(TM)
sensors, USBCam(TM) intra-oral cameras and accuDEXA(R) bone densitometers at
this manufacturing facility. The Company outsources the assembly of certain
subassemblies, such as
4
printed circuit boards, plastics and cables, but performs the majority of the
final assembly and testing process at its manufacturing facility.
The Company purchases components for its products from a number of outside
vendors. While the Company strives to maintain multiple sources of supply for
each component, certain highly specialized components, including semiconductor
wafers used in the assembly of sensors, are primarily provided by a single
supplier. In these cases, the Company strives to maintain sufficient inventory
so as to provide extra time in which to locate an acceptable alternate supplier
in the event of a supply interruption. The Company believes that it would be
able to locate an acceptable alternate supplier in such event; however, the need
to replace a supplier could cause a disruption in the Company's ability to
timely deliver its products or increase the Company's costs.
The Company's quality assurance program includes various quality control
measures, from inspection of raw materials, purchased parts and assemblies
through in-process and final inspection, and conforms to the guidelines of the
International Quality Standard, ISO 9001. In August 1998, the Company was
granted ISO 9001 certification and, in September 2003, was granted ISO 9001:2000
certification. Since August 1998, the Company has been subject to semi-annual
audits to evaluate its eligibility to maintain such certification.
DEPENDENCE ON CUSTOMERS
During fiscal 2004, 2003 and 2002, respectively, North American sales of
approximately $21.6 million or 55% of total annual sales, $15.4 million or 52%
of total annual sales and $9.9 million or 41% of total annual sales, were made
to Patterson Dental Company. During fiscal 2004, 2003 and 2002 respectively,
sales of approximately $9.9 million, $6.2 million and $6.2 million were made to
international customers.
PATENTS, TRADE SECRETS AND PROPRIETARY RIGHTS
The Company seeks to protect its intellectual property through a
combination of patent, trademark and trade secret protection. The Company's
future success will depend in part on its ability to obtain and enforce patents
for its products and processes, preserve its trade secrets and operate without
infringing the proprietary rights of others.
Patents
The Company has an active corporate patent program, the goal of which is
to secure patent protection for its technology. The Company currently has issued
United States patents for an `Intra-Oral Sensor For Computer Aided Radiography',
U.S. Patent No. 5,434,418, which expires on October 16, 2012; a `Large Area
Image Detector', U.S. Patent No. 5,834,782, which expires on November 20, 2016;
a `Method and Apparatus for Measuring Bone Density', U.S. Patent No. 5,852,647,
which expires on September 24, 2017; an `Apparatus for Measuring Bone Density
Using Active Pixel Sensors', U.S. Patent No. 5,898,753, which expires on June 6,
2017; a `Dental Imaging System with Lamps and Method', U.S. Patent No.
5,908,294, which expires on June 12, 2017; an `X-ray Detection System Using
Active Pixel Sensors', U.S. Patent No. 5,912,942, which expires on June 6, 2017;
a `Dental Imaging System with White Balance Compensation', U.S. Patent No.
6,002,424, which expires on June 12, 2017; `Dental Radiography Using an
Intraoral Linear Array Sensor,' U.S. Patent No. 5,995,583, which expires on
November 13, 2016; a `Method for Reading Out Data from an X-Ray Detector,' U.S.
Patent No. 6,069,935, which expires on November 2, 2018; and a `Filmless Dental
Radiography System Using Universal Serial Bus Port', U.S. Patent No. 6,134,298,
which expires on August 7, 2018. In addition, the Company is the licensee of
U.S. Patent No. 5,179,579, for a `Radiograph Display System with Anatomical Icon
for Selecting Digitized Stored Images', under a worldwide, non-exclusive, fully
paid license. The Company also has ten U.S. patent applications currently
pending. The Company also seeks foreign patent protection when it deems it to be
warranted.
5
The Company is the exclusive sub-licensee for use in medical radiography
applications of certain patents, patent applications and other know-how
(collectively, the "Intellectual Property") related to complementary metal oxide
semiconductor ("CMOS") active pixel sensor technology (the "APS Technology"),
which was developed by the California Institute of Technology and licensed to
Photobit Corp. from which the Company obtained its sub-license. Photobit was
subsequently acquired by Micron Technology, Inc., which continues to sublicense
the CMOS Intellectual Property to the Company. The Company's exclusive rights to
such technology are subject to government rights to use, noncommercial
educational and research rights to use by California Institute of Technology and
the Jet Propulsion Laboratory, and the right of a third party to obtain a
nonexclusive license from the California Institute of Technology with respect to
such technology. The Company believes that, except for such third party's
exercise of its right to obtain a nonexclusive license to use APS Technology in
a field other than medical radiography, none of the foregoing parties have given
notice of their exercise of any of their respective rights to the APS
Technology. There can be no assurance that this will continue to be the case,
and any such exercise could have a material adverse effect on the Company.
Additionally, the agreement between the Company and Photobit Corporation
required, among other things, that the Company use all commercially reasonable
efforts to timely introduce, improve and market and distribute licensed products
in various fields. The Company has not introduced licensed products in certain
of these fields, and there can be no assurance that the Company will do so in
the future. Such failure to introduce licensed products could result in a
termination or modification of the Company's rights with respect to the fields
in which it has not introduced licensed products, but should not affect the
Company's rights with respect to the fields in which it has introduced licensed
products.
Trademarks
The Company has obtained trademark registrations from the United States
Patent and Trademark Office for the marks (i) "CDR" for its digital dental
radiography product; (ii) "CDRCam" (both textual and stylized) for its
intra-oral camera (iii) "QuickZoom" (both textual and stylized) for a viewing
feature in its digital dental radiography product; (iv) "accuDEXA" for its BMD
assessment product; and (v) "CDRPan" for its panoramic digital dental
radiography product. In addition, the Company has a pending trademark
application as well as common law trademark rights in several other names it
uses commercially in connection with its products.
Trade Secrets
In addition to patent protection, the Company owns trade secrets and
proprietary know-how which it seeks to protect, in part, through appropriate
Non-Disclosure, Non-Solicitation, Non-Competition and Inventions Agreements,
and, to a limited degree, employment agreements with appropriate individuals.
These agreements generally provide that all confidential information developed
by or made known to the individual by the Company during the course of the
individual's relationship with the Company is the property of the Company, and
is to be kept confidential and not disclosed to third parties, except in
specific limited circumstances. The agreements also generally provide that all
inventions conceived by the individual in the course of rendering services to
the Company shall be the exclusive property of the Company. However, there can
be no assurances that these agreements will not be breached, that the Company
would have adequate remedies available for any breach or that the Company's
trade secrets will not otherwise become known to, or independently developed by,
its competitors.
GOVERNMENT REGULATION
Products that the Company is currently developing or may develop in the
future are likely to require certain forms of governmental clearance, including,
but not limited to, marketing clearance by the United States Food and Drug
Administration (the "FDA"). The FDA review process typically requires extended
proceedings pertaining to product safety and efficacy. The Company believes that
its future success will depend to a large degree upon commercial sales of
improved versions of its current products and sales of new products; the Company
will not be able to market such products in the United States without FDA
6
marketing clearance. There can be no assurance that any products developed by
the Company in the future will be given clearance by applicable governmental
authorities or that additional regulations will not be adopted or current
regulations amended in such a manner as to adversely affect the Company.
Pursuant to the Federal Food, Drug and Cosmetic Act, as amended (the "FD&C
Act"), the FDA classifies medical devices intended for human use into three
classes: Class I, Class II, and Class III. In general, Class I devices are
products for which the FDA determines that safety and effectiveness can be
reasonably assured by general controls under the FD&C Act relating to such
matters as adulteration, misbranding, registration, notification, records and
reports. The USBCam(TM) is a Class I device.
Class II devices are products for which the FDA determines that general
controls are insufficient to provide a reasonable assurance of safety and
effectiveness, and that require special controls such as promulgation of
performance standards, post-market surveillance, patient registries or such
other actions as the FDA deems necessary. The CDR(R) system, CDRPan(R),
CDRPanX(TM) and accuDEXA(R) have been classified as Class II devices.
Class III devices are devices for which the FDA has insufficient
information to conclude that either general controls or special controls would
be sufficient to assure safety and effectiveness, and which are life-supporting,
life-sustaining, of substantial importance in preventing impairment of human
health, or present a potential unreasonable risk of illness or injury. Devices
in this class require pre-market approval, as described below. None of the
Company's existing products are in the Class III category.
The FD&C Act further provides that, unless exempted by regulation, medical
devices may not be commercially distributed in the United States unless they
have been cleared by the FDA. There are two review procedures by which medical
devices can receive such clearance. Some products may qualify for clearance
under a Section 510(k) procedure, in which the manufacturer submits to the FDA a
pre-market notification that it intends to begin marketing the product, and
shows that the product is substantially equivalent to another legally marketed
product (i.e., that it has the same intended use and that it is as safe and
effective as a legally marketed device, and does not raise different questions
of safety and effectiveness than does a legally marketed device). In some cases,
the 510(k) notification must include data from human clinical studies.
Marketing may commence once the FDA issues a clearance letter finding such
substantial equivalence. According to FDA regulations, the agency has 90 days in
which to respond to a 510(k) notification. There can be no assurance, however,
that the FDA will provide a timely response, or that it will reach a finding of
substantial equivalence.
If a product does not qualify for the 510(k) procedure (either because it
is not substantially equivalent to a legally marketed device or because it is a
Class III device), the FDA must approve a Pre-Market Approval ("PMA")
application before marketing can begin. PMA applications must demonstrate, among
other things, that the medical device is safe and effective. A PMA application
is typically a complex submission that includes the results of clinical studies.
Preparation of such an application is a detailed and time-consuming process.
Once a PMA application has been submitted, the FDA's review process may be
lengthy and include requests for additional data. By statute and regulation, the
FDA may take 180 days to review a PMA application, although such time may be
extended. Furthermore, there can be no assurance that the FDA will approve a PMA
application.
In January 1994, the FDA cleared the Company's 510(k) application for
general use and marketing of the CDR(R) system, and in October 2002, cleared the
Company's expanded 510(k) application for the CDR wireless product. In November
1996, the FDA cleared the Company's 510(k) application for general use and
marketing of the USBCam(TM). In December 1997, the FDA cleared the Company's
510(k) application for general use and marketing of accuDEXA(R). The FDA granted
the Company additional clearances in connection with the accuDEXA(R), on June 4,
1998, to market accuDEXA(R) as a predictor of fracture risk, and on May 26,
2000, to further clarify issues regarding the collection of the normative
database. In
7
December 1998 and May 2003, the FDA cleared the Company's 510(k) applications
for CDRPan(R) and CDRPanX(TM), respectively.
In addition to the requirements described above, the FD&C Act requires
that all medical device manufacturers and distributors register with the FDA
annually and provide the FDA with a list of those medical devices which they
distribute commercially. The FD&C Act also requires that all manufacturers of
medical devices comply with labeling requirements and manufacture their products
and maintain their documents in a prescribed manner with respect to
manufacturing, testing, and quality control activities. The FDA's Medical Device
Reporting regulation subjects medical devices to post-market reporting
requirements for death or serious injury, and for certain malfunctions that
would be likely to cause or contribute to a death or serious injury if
malfunction were to recur. In addition, the FDA prohibits a device which has
received marketing clearance from being marketed for applications for which
marketing clearance has not been obtained. Furthermore, the FDA generally
requires that medical devices not cleared for marketing in the United States
receive FDA marketing clearance before they are exported, unless an export
certification has been granted.
The Company must obtain certain approvals by and marketing clearances from
governmental authorities, including the FDA and similar health authorities in
foreign countries, to market and sell its products in those countries. The FDA
regulates the marketing, manufacturing, labeling, packaging, advertising, sale
and distribution of "medical devices", as do various foreign authorities in
their respective jurisdictions. The FDA enforces additional regulations
regarding the safety of equipment utilizing x-rays. Various states also impose
similar regulations.
The FDA review process typically requires extended proceedings pertaining
to the safety and efficacy of new products. A 510(k) application is required in
order to market a new or modified medical device. If specifically required by
the FDA, a pre-market approval ("PMA") may be necessary. Such proceedings, which
must be completed prior to marketing a new medical device, are potentially
expensive and time consuming. They may delay or hinder a product's timely entry
into the marketplace. Moreover, there can be no assurance that the review or
approval process for these products by the FDA or any other applicable
governmental authorities will occur in a timely fashion, if at all, or that
additional regulations will not be adopted or current regulations amended in
such a manner as will adversely affect the Company. The FDA also regulates the
content of advertising and marketing materials relating to medical devices.
Failure to comply with such regulations may result in a delay in obtaining
approval for the marketing of such products or the withdrawal of such approval
if previously obtained.
The Company is currently developing new products for the dental and
medical markets. The Company expects to file 510(k) applications with the FDA in
connection with its future products. There can be no assurance that the Company
will file such 510(k) applications and/or will obtain pre-market clearance for
any future products, or that in order to obtain 510(k) clearance, the Company
will not be required to submit additional data or meet additional FDA
requirements that may substantially delay the 510(k) process and result in
substantial additional expense. Moreover, such pre-market clearance, if
obtained, may be subject to conditions on marketing or manufacturing, which
could impede the Company's ability to manufacture and/or market the product. If
the Company is unable to obtain regulatory approval for and market new products
and enhancements to existing products, it will have a material adverse effect on
the Company.
The Company's CDR(R) wireless product complies with the relevant technical
standards established by the U.S. Federal Communications Commission ("FCC"), as
set forth in FCC Rule 15.249. CDR wireless is not subject to any wireless or
transmission licensing requirements.
Failure to comply with applicable regulatory requirements can, among other
consequences, result in fines, injunctions, civil penalties, suspensions or loss
of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution. In addition, governmental regulations may
be established that could prevent or delay regulatory clearance of the Company's
products. Delays in receipt
8
of clearance, failure to receive clearance or the loss of previously received
clearance would have a material adverse effect on the Company's business,
financial condition and results of operations.
In addition to laws and regulations discussed above, the Company is
subject to government regulations applicable to all businesses, including, among
others, regulations related to occupational health and safety, workers' benefits
and environmental protection. The extent of government regulation that might
result from any future legislation or administrative action cannot be accurately
predicted. Failure to comply with regulatory requirements could have a material
adverse effect on the Company's business, financial condition and results of
operations.
Distribution of the Company's products in countries other than the United
States may be subject to regulations in those countries. These regulations vary
significantly from country to country; the Company typically relies on its
independent distributors in such foreign countries to obtain the requisite
regulatory approvals.
The Company's products bear the "CE Mark," a European Union symbol of
compliance with quality assurance standards and with the European Union's
Medical Device Directive ("MDD"). In order to market the Company's products in
the member countries of the European Union, it is necessary that those products
conform to these standards and the MDD. It is also necessary that the Company's
products comply with any revisions which may be made to the standards or the
MDD. To date, the Company has maintained such compliance.
The Company has developed and implemented a quality assurance program in
accordance with the guidelines of the International Quality Standard, ISO 9001.
In August 1998, the Company was granted ISO 9001 certification. The Company's
current products also comply with the requirements for the "U.L." 2601-1
(U.S.A.) and "CSA" C22.2 No. 601-1 (Canada) standards and bear the "ETL" mark
indicating such compliance.
PRODUCT LIABILITY INSURANCE
The Company is subject to the risk of product liability and other
liability claims in the event that the use of its products results in personal
injury or other claims. Although the Company has not experienced any product
liability claims to date, any such claims could have an adverse impact on the
Company. The Company maintains insurance coverage related to product liability
claims, but there can be no assurance that product liability or other claims
will not exceed its insurance coverage limits, or that such insurance will
continue to be maintained or that it will be available on commercially
acceptable terms, or at all.
RESEARCH AND DEVELOPMENT
During fiscal 2004, 2003 and 2002, research and development expenses were
$3.3, $2.6 and $2.2 million, respectively.
BACKLOG
The backlog of orders was approximately $0.8 million at June 10, 2004 and
$0.5 million at each of June 3, 2003 and June 1, 2002, respectively. Such
figures include approximately $0.4 million, $0.2 million, and $0.4 million of
orders on hold pending credit approval at June 3, 2004, June 3, 2003 and June 1,
2002, respectively. Orders included in backlog may generally be cancelled or
rescheduled by customers without significant penalty.
EMPLOYEES
As of June 10, 2004, the Company had 133 full-time employees, engaged in
the following capacities: sales and marketing (40); general and administrative
(32); operations (37); and research and development
9
(24). The Company believes that its relations with its employees are good. No
Company employees are represented by a labor union or are subject to a
collective bargaining agreement, nor has the Company experienced any work
stoppages due to labor disputes.
SALES AND MARKETING
Dental Products
In April 2000, the Company and Patterson Dental Company ("Patterson")
entered into an exclusive distribution agreement covering the United States and
Canada; as of May 1, 2000, the Company began marketing and selling its CDR(R)
dental products in the United States and Canada through Patterson. The Company
believes that Patterson is one of the largest distributors of dental products in
North America, with more than 1,200 field sales personnel in the U.S. and
Canada. In addition, the Company has an in-house sales program that focuses on
universities and continuing education programs. As of March 31, 2004, CDR(R) had
been sold to 47 of the 55 dental schools in the United States. The Company also
employs a government sales program to sell directly to the Armed Services,
Veterans Administration hospitals, United States Public Health Service and other
government-sponsored health institutions.
The Company currently has 16 area sales manager ("ASM") territories
located throughout the United States and one in Canada to interface with and
assist Patterson in its sales effort; two individuals manage the ASM staff. In
addition, a sales and marketing support staff of seven, based at the Company's
offices in New York and at other locations throughout the United States,
supports the sales managers and the ASMs by planning events and product seminars
and developing promotional and marketing materials.
In the international market, the Company sells the CDR(R) system via
independent regional distributors. There are currently approximately 65
independent CDR(R) dealers, covering about 57 countries. A dedicated in-house
staff, as well as four individuals based in Europe, Asia and Latin America,
provide the foreign distributors with materials, sales support, technical
assistance and training, both in New York and abroad.
The Company's goal is to develop and introduce new technologies and
products while maintaining market leadership in our core domestic business,
strengthening and expanding our international distribution network and securing
as many productive sales channels as possible.
BMD / Fracture Risk Assessment
The Company currently sells the accuDEXA(R) primarily through a network of
manufacturer representatives. To date, accuDEXA(R) sales have taken place
primarily within the United States, with a relatively small number of sales
abroad. The primary end-users for accuDEXA(R) are primary care physicians,
including OB/GYN practices, and osteopathic and geriatric specialists.
COMPETITION
Competition relating to the Company's current products is intense and
includes various companies, both within and outside of the United States. Many
of the Company's competitors are large companies with financial, sales and
marketing, and other resources that are substantially greater than those of the
Company. In addition, there can be no assurance that the Company's competitors
are not currently developing, or will not attempt to develop, technologies and
products that are more effective than those of the Company or that would
otherwise render the Company's products obsolete or noncompetitive. No assurance
can be given that the Company will be able to compete successfully.
10
Dental Products
A number of companies currently sell intra-oral digital dental sensors
under various brand names. These include Eastman Kodak Co. ("Trophy"), Gendex
Dental Systems ("DenOptix"), Dentrix Dental Systems, Inc. ("ImageRay"),
Provisions Dental Systems, Inc. ("Dexis"), Sirona Dental Systems ("Sidexis") and
Suni Imaging, Inc. In addition, Gendex, Air Techniques and Soredex Corporation
sell storage-phosphor based intra-oral dental systems. The Company believes that
its CDR system has thus far competed successfully against other products. If
other companies enter the digital radiography field, it may result in a
significantly more competitive market in the future. Several companies are
involved in the manufacture and sale of intra-oral cameras, including Gendex,
Henry Schein, Inc., Digital Doc and Air Techniques. Several companies, including
Kodak, Sirona, Signet, Instrumentarium Imaging and Planmeca, manufacture digital
panoramic dental devices.
BMD / Fracture Risk Assessment
Two other companies, GE Lunar Corporation and Cooper-Surgical, Inc., are
currently marketing peripheral dual-X-Ray-absorptiometry (DXA) BMD
densitometers. Several companies including GE Lunar, Hologic, Inc., Sunlight,
Inc. and Norland are marketing peripheral ultrasound devices. A number of other
companies market other devices including ones that assess hand densitometry. Two
companies, Ostex International Inc. and Quidel Corp., Inc., have developed
biochemical markers which indicate the rate at which the body is resorbing
(i.e., breaking down) bone.
ITEM 2. PROPERTIES
The Company presently leases approximately 50,000 square feet of space in
Long Island City, New York. That lease expires in June 2007. The leased space
houses our executive offices, sales and marketing headquarters, research and
development laboratories and production and shipping facilities. The Company
believes that such space will be adequate for its needs for the foreseeable
future and that, if such space proves to be inadequate, it will be able to
procure additional or replacement space that will be adequate for its needs.
ITEM 3. LEGAL PROCEEDINGS
The Company and/or certain of its officers and former officers, are
involved in the matters described below:
In August 1999, the Company, through its outside counsel, contacted the
Division of Enforcement of the Securities and Exchange Commission ("SEC") to
advise it of certain matters related to the Company's restatement of earnings
for interim periods of fiscal 1999. Subsequent thereto, the SEC requested the
voluntary production of certain documents and the Company provided the SEC with
the requested materials. On August 17, 2000 and April 30, 2003, the SEC served
subpoenas upon the Company, pursuant to a formal order of investigation,
requiring the production of certain documents. The Company timely provided the
SEC with the subpoenaed materials. The Company has been informed that since
January 2002 the SEC and/or the United States Attorney's Office for the Southern
District of New York have served subpoenas upon and/or contacted certain
individuals, including current and former officers and employees of the Company,
and a current Director, in connection with this matter. On June 13, 2002, the
Company was advised by counsel to David Schick, the Company's former chief
executive officer, that the United States Attorney's Office for the Southern
District of New York had notified such counsel that Mr. Schick was a target of
the United States Attorney's investigation of this matter. The Company has
cooperated with the SEC staff and U.S. Attorney's Office.
On November 14, 2003, the SEC filed a civil action in the United States
District Court for the Eastern District of New York against the Company, its
former chief executive officer, and its former vice president of sales &
marketing. The SEC complaint alleges fraud, and books and records and reporting
violations
11
under Sections 10(b), 13(a) and 13(b)(2) of the Securities Exchange Act and
various rules promulgated thereunder in connection with the financial statements
included in the Company's reports on Form 10-Q for the quarters ended June 30,
September 30 and December 31, 1998. The SEC complaint seeks to enjoin the
Company from future violations of those provisions of the Exchange Act and the
rules thereunder, as well as disgorgement of any ill-gotten gains, which the
Company does not believe to be material in amount. With respect to the other
defendants, the complaint seeks injunctive relief, civil penalties, disgorgement
and an officer/director bar.
In September 2003, the Board of Directors appointed a Special Litigation
Committee, consisting of Messrs. Blank (Chair), Hood, Landesman and Rocca, which
has oversight responsibility and authority with respect to the SEC/U.S. Attorney
matter. The Company promptly commenced discussions with the SEC's northeast
regional office in an effort to resolve the complaint against the Company. There
can be no assurance that those discussions will continue and/or will be
successful. The Company will continue to incur significant legal fees and may
incur indemnification costs. However, the Company believes that the magnitude of
such expenditures will not adversely affect its ongoing business operations.
The Company cannot predict the potential outcome of these matters and
their impact on the Company and, therefore, has made no provision relating to
these matters in the accompanying consolidated financial statements.
The Company could become a party to a variety of legal actions (in
addition to that referred to above), such as employment and employment
discrimination-related suits, employee benefit claims, breach of contract
actions, tort claims, shareholder suits, including securities fraud, and
intellectual property related litigation. In addition, because of the nature of
its business, the Company is subject to a variety of legal actions relating to
its business operations. Recent court decisions and legislative activity may
increase the Company's exposure for any of these types of claims. In some cases,
substantial punitive damages could be sought. The Company currently has
insurance coverage for some of these potential liabilities. Other potential
liabilities may not be covered by insurance, insurers may dispute coverage, or
the amount of insurance may not be sufficient to cover the damages awarded. In
addition, certain types of damages, such as punitive damages, may not be covered
by insurance and insurance coverage for all or certain forms of liability may
become unavailable or prohibitively expensive in the future.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders during the quarter
ended March 31, 2004.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Since January 30, 2002, the Company's Common Stock has been traded on the
over-the-counter Bulletin Board under the symbol "SCHK".
The following table sets forth, for the periods indicated, the high and
low bid prices of the Company's Common Stock as quoted on the over-the-counter
Bulletin Board for each of the fiscal quarters during the years ended March 31,
2004 and 2003.
Fiscal Year Ended March 31, 2004 High Low
-------------------------------- ------ ------
First Quarter ........................................ $ 8.80 $ 4.30
Second Quarter ....................................... $ 8.58 $ 6.85
Third Quarter ........................................ $ 8.40 $ 6.50
Fourth Quarter ....................................... $12.15 $ 7.05
12
Fiscal Year Ended March 31, 2003 High Low
-------------------------------- ------ ------
First Quarter ........................................ $ 3.60 $ 2.10
Second Quarter ....................................... $ 3.01 $ 1.10
Third Quarter ........................................ $ 3.00 $ 1.78
Fourth Quarter ....................................... $ 4.75 $ 2.72
On June 10, 2004, the closing bid and asked prices per share of the
Company's Common Stock, as quoted on the over-the-counter Bulletin Board, were
$12.05 and $12.40 per share, respectively. Such prices represent quotations
between dealers, without dealer mark-up, markdown or commission, and may not
represent actual transactions. On June 10, 2004, there were one hundred
seventy-one (171) holders of record of the Company's Common Stock. However, the
Company believes that the number of beneficial owners of such stock is
substantially higher.
To date, the Company has retained its earnings to finance the growth and
development of the Company's business, and has not paid any dividends on its
Common Stock. The Company may consider paying dividends in the future, but
currently has no plans to do so. The payment of dividends is within the
discretion of the Board of Directors and will depend upon the Company's
earnings, its capital requirements, financial condition and other relevant
factors.
Equity Compensation Plan Information
The following table sets forth the following information, as of March 31,
2004, with respect to compensation plans (including individual compensation
arrangements) under which equity securities of the Company are authorized for
issuance: the number of securities to be issued upon the exercise of outstanding
options, warrants and rights; the weighted-average exercise price of such
options, warrants and rights; and, other than the securities to be issued upon
the exercise of such options, warrants and rights, the number of securities
remaining available for future issuance under the plan:
---------------------------------------------------------------------------------------------------------------
(a) (b) (c)
---------------------------------------------------------------------------------------------------------------
Plan category Number of Weighted-average Number of securities
securities to be exercise price remaining available
issued upon of outstanding for future issuance
exercise of options, under equity
outstanding warrants and compensation plans
options, rights (excluding
warrants and securities reflected
rights in column (a))
---------------------------------------------------------------------------------------------------------------
Equity compensation plans approved 2,124,264 $3.36 1,475,736
by security holders
---------------------------------------------------------------------------------------------------------------
Equity compensation plans not approved
by security holders -- -- --
---------------------------------------------------------------------------------------------------------------
Total 2,124,264 $3.36 1,475,736
---------------------------------------------------------------------------------------------------------------
In addition to the options described in the table above, the Company has
outstanding an aggregate of 847,500 warrants, exercisable at an initial exercise
price of $0.75 per share, which are held by the Company's CEO, as assignee of
Greystone Funding Corporation ("Greystone"). During fiscal 2004, Greystone
exercised 4,802,500 warrants. Such warrants, which are described in Note 10 to
the Company's Consolidated Financial Statements, were issued by the Company in
connection with loan transactions.
13
ITEM 6. SELECTED FINANCIAL DATA
The following selected financial data are derived from, and are qualified
by reference to, the audited financial statements of the Company for the period
indicated. The information presented below should be read in conjunction with
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" in Item 7 and the Financial Statements included in Item 15 of this
Report.
Schick Technologies, Inc.
Selected Financial Data
Year ended March 31,
2004 2003 2002 2001 2000
-------- -------- -------- -------- --------
(in thousands, except per share data)
Statement of Operations Data:
Revenue, net $ 39,393 $ 29,817 $ 24,399 $ 21,252 $ 21,989
Cost of sales 11,310 9,369 8,540 9,736 15,393
Excess and obsolete inventory 185 259 292 570 898
-------- -------- -------- -------- --------
Total cost of sales 11,495 9,628 8,832 10,306 16,291
-------- -------- -------- -------- --------
Gross profit 27,898 20,189 15,567 10,946 5,698
Operating expenses:
Selling and marketing 6,118 5,911 5,291 5,314 7,636
General and administrative 6,291 5,041 4,148 4,161 7,339
Research and development 3,301 2,598 2,176 2,220 2,830
Bad debt expense (recovery) 105 -- (93) (454) --
Abandonment of leasehold -- -- 118 275 --
-------- -------- -------- -------- --------
Total operating expenses 15,815 13,550 11,640 11,516 17,805
-------- -------- -------- -------- --------
Income (loss) from operations 12,083 6,639 3,927 (570) (12,107)
Total other income (expense) 109 (174) (839) (1,068) (224)
-------- -------- -------- -------- --------
Income (loss) before income taxes 12,192 6,465 3,088 (1,638) (12,331)
Income tax benefit 5,917 5,360 -- -- --
-------- -------- -------- -------- --------
Net income (loss) $ 18,109 $ 11,825 $ 3,088 $ (1,638) $(12,331)
======== ======== ======== ======== ========
Basic earnings (loss) per share $ 1.69 $ 1.17 $ 0.30 $ (0.16) $ (1.23)
======== ======== ======== ======== ========
Diluted earnings (loss) per share $ 1.07 $ 0.78 $ 0.26 $ (0.16) $ (1.23)
======== ======== ======== ======== ========
As at March 31,
2004 2003 2002 2001 2000
-------- -------- -------- -------- --------
Balance Sheet Data:
Cash and cash equivalents $ 20,734 $ 7,100 $ 1,622 $ 2,167 $ 1,429
Working capital / (deficiency) 27,400 9,157 1,133 (1,586) 841
Total assets 42,743 22,610 11,957 12,646 16,290
Long-term obligations -- -- 2,039 4,080 6,938
Total liabilities 7,715 7,747 9,057 12,835 14,974
Retained earnings (accumulated deficit) (9,748) (27,857) (39,682) (42,770) (41,132)
Stockholders' equity 35,028 14,863 2,900 (189) 1,316
14
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read in conjunction with the
Consolidated Financial Statements included elsewhere in this Report. This
discussion contains forward-looking statements based on current expectations
that involve risks and uncertainties. Actual results and the timing of certain
events may differ significantly from those projected in such forward-looking
statements due to a number of factors, including those set forth in "Results of
Operations" in this Item and elsewhere in this Report. See "ITEM 1 -- Business
-- Forward-Looking Statements" and Exhibit 99.1 to this Report.
Overview
The Company designs, develops and manufactures digital imaging systems for
the worldwide dental and medical markets. In the field of dentistry, the Company
currently manufactures and markets a variety of digital imaging products
including an intra-oral digital radiography system (CDR(R) and CDR
Wireless(TM)), a digital panoramic radiography sensor (CDRPan(R)) and integrated
device (CDRPanX(TM)) and an intra-oral camera system (USBCam(TM)). The Company
has also developed a bone mineral density assessment device (accuDEXA(R)) to
assist in the diagnosis and treatment of osteoporosis, which was introduced in
December 1997. The Company's revenues during fiscal 2004 were derived primarily
from sales of its CDR(R) system.
The Company records sales revenue upon shipment to international dealers
and to end-users in the U.S. In the case of sales made by Patterson, revenue
arising from inventory in Patterson's possession is recorded in deferred
revenue, and revenue is recognized upon shipment from Patterson's distribution
centers. Revenues from the sales of extended warranties are recognized on a
straight-line basis over the life of the extended warranty, which is generally a
one-year period. The Company utilizes Patterson as the exclusive distributor for
sales of its dental products within the United States and Canada. The Company's
accuDEXA(R) product is sold through a network of independent sales
representatives in the United States. International sales are made primarily
through a network of independent foreign distributors. In fiscal 2004, 2003, and
2002, sales to customers within the United States were approximately 75%, 78%
and 75% of total revenues, respectively. The Company's international sales are
made primarily to distributors in Europe and Asia. All of the Company's sales
are primarily denominated in United States dollars.
Cost of sales consists of raw materials, manufacturing labor, facilities
overhead, product support, and warranty costs. Excess and obsolete inventory
expense relates to the overstocking or obsolescence of various dies and/or
obsolete x-ray inventory that the Company may not use or otherwise salvage.
Operating expenses include selling and marketing expenses, general and
administrative expenses and research and development expenses, and bad debt
expense. Selling and marketing expenses consist of salaries and commissions,
advertising, promotional and sales events and travel. General and administrative
expenses include executive salaries, professional fees, facilities, overhead,
accounting, human resources, and general office administration expenses.
Research and development expenses are comprised of salaries, consulting fees,
facilities overhead and testing materials used for basic scientific research and
the development of new and improved products and their uses. Research and
development costs are expensed as incurred. Bad debt expense is a result of
product shipments that were determined to be uncollectible or not collected. Bad
debt recovery is a result of the receipt, in cash, for shipments previously
deemed uncollectible.
Critical Accounting Policies
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires the Company to make
estimates and assumptions that affect amounts reported in the accompanying
consolidated financial statements and related footnotes. These estimates and
assumptions are evaluated on an ongoing basis based on historical developments,
market conditions,
15
industry trends and other information the Company believes to be reasonable
under the circumstances. There can be no assurance that actual results will
conform to the Company's estimates and assumptions, and that reported results of
operations will not be materially adversely affected by the need to make
accounting adjustments to reflect changes in these estimates and assumptions
from time to time. The following policies are those that the Company believes to
be the most sensitive to estimates and judgments. The Company's significant
accounting policies are more fully described in Note 1 to the consolidated
statements.
Revenue recognition
The Company recognizes revenue when each of the following four criteria
are met: 1) a contract or sales arrangement exists; 2) products have been
shipped and title has been transferred or services have been rendered; 3) the
price of the products or services is fixed or determinable; and 4)
collectibility is reasonably assured. Revenues from sales of the Company's
hardware and software products are recognized at the time of shipment to
customers, and when no significant obligations exist and collectibility is
probable. The Company provides its exclusive domestic distributor with a 30-day
return policy but allows for an additional 15 days, and accordingly recognizes
allowances for estimated returns pursuant to such policy at the time of
shipment. Revenue from shipments to foreign customers is recognized at the time
of shipment in accordance with foreign sales orders. With respect to products
shipped to its exclusive domestic distributor, the Company defers revenue until
Patterson ships such inventory from its distribution centers. Amounts received
from customers in advance of product shipment are classified as deposits from
customers. Revenues from the sale of extended warranties on the Company's
products are recognized on a straight-line basis over the life of the extended
warranty, which is generally a one-year period. Deferred revenues relate to
extended warranty fees paid by customers prior to the performance of extended
warranty services, to certain shipments to Patterson, as described above, and to
the 90-day exchange program for CDR(R) wireless, as follows: Patterson
instituted a policy permitting, under specific circumstances, the exchange of
CDR(R) wireless products, sold after October 23, 2003, for wired CDR(R)
products. This exchange is allowed for a period of 90 days from the date of
installation in the event that external radio-frequency sources cause
interference that cannot be resolved. Accordingly, the Company has deferred
recognition of revenue related to Patterson's shipment of the CDR(R) wireless
product until the foregoing 90-day period has elapsed.
Accounts receivable
The Company primarily sells on open credit terms to Patterson and to the
U.S. Government, and upon signed purchase orders to hospitals and universities.
The Company's international sales are generally prepaid, guaranteed by
irrevocable letter of credit or underwritten by credit insurance. In a limited
number of cases, international dealers are granted open credit terms. Warranty
shipments are prepaid. Revenue from customers is subject to agreements allowing
limited rights of return. Accordingly, the Company reduces revenue recognized
for estimated future returns. The estimate of future returns is adjusted
periodically based upon historical rates of return. The Company provides an
allowance for doubtful accounts based upon its analysis of aged accounts
receivable.
Inventories
Inventories are stated at the lower of cost or market. The cost of
inventories is determined principally on the standard cost method for
manufactured goods and on the average cost method for other inventories, each of
which approximates actual cost on the first-in, first-out ("FIFO") method. The
Company establishes reserves for inventory estimated to be obsolete,
unmarketable or slow moving inventory equal to the difference between the cost
of inventory and estimated market value based upon assumptions about future
demand and market conditions. If actual market conditions are less favorable
than those anticipated or if changes in technology affect the Company's
products, additional inventory reserves could be required.
16
Goodwill and other long-lived assets
Effective April 1, 2002, the Company adopted Statement of Financial
Accounting Standards No. 142 ("SFAS 142"), "Goodwill and other Intangible
Assets". This statement requires that the amortization of goodwill be
discontinued and instead an annual impairment approach be applied. The
impairment tests were performed upon adoption and are performed annually
thereafter (or more often if adverse events occur) and will be based upon a fair
value approach rather than an evaluation of undiscounted cash flows. If the
asset has been impaired, the resulting charge reflects the excess of the asset's
carrying value over the recalculated goodwill. Impairment tests performed in
August 2002, March 2003 and March 2004 indicated that goodwill had not been
impaired.
Other long-lived assets, such as patents and property and equipment, are
amortized or depreciated over their estimated useful lives. These assets are
reviewed for impairment whenever events or circumstances provide evidence that
suggest that the carrying amount of the asset may not be recoverable, with
impairment being based upon an evaluation of the identifiable undiscounted cash
flows. If the asset has been impaired, the resulting charge reflects the excess
of the asset's carrying cost over its fair value.
If market conditions become less favorable, future cash flows, the key
variable in assessing the impairment of these assets, may decrease and as a
result the Company may be required to recognize impairment charges.
Deferred tax asset and income taxes
Income taxes are determined in accordance with Statement of Financial
Accounting Standards No. 109 ("SFAS 109"), which requires recognition of
deferred income tax liabilities and assets for the expected future tax
consequences of events that have been included in the financial statements or
tax returns. Under this method, deferred income tax liabilities and assets are
determined based on the difference between financial statements and tax bases of
liabilities and assets using enacted tax rates in effect for the year in which
the differences are expected to reverse. SFAS 109 also provides for the
recognition of deferred tax assets if it is more likely than not that the assets
will be realized in future years. Through March 31, 2003, a valuation allowance
of $11.4 million was established for deferred tax assets for which it was not
more likely than not that the deferred tax asset would be realized. During the
year ended March 31, 2003 the Company reduced its valuation allowance by $5.8
million. At March 31, 2004, the Company reduced its valuation allowance by $6.6
million, to zero, because it determined that it was more likely than not that
the total deferred tax would be realized. During fiscal 2004, 2003 and 2002, the
Company's utilization of its net operating losses resulted in a reduction of
current taxes in the amount of $4.8 million, $2.7 million and $1.5 million,
respectively. In assessing the valuation allowance, the Company has considered
future taxable income and ongoing tax planning strategies and has determined
that it is more likely than not that the deferred tax asset will be realized.
Changes in these circumstances, such as a decline in future taxable income, may
result in the reestablishment of a valuation allowance.
Warranty obligations
Products sold are generally covered by a warranty against defects in
material and workmanship for a period of one year. The Company accrues a
warranty reserve for estimated costs to provide warranty services. The Company
estimates costs to service warranty obligations based on historical experience
and expectation of future conditions. To the extent the Company experiences
increased warranty claim activity or increased costs associated with servicing
those claims, warranty accrual will increase, resulting in decreased gross
profit.
Stock-based compensation
Stock based compensation is accounted for under the recognition and
measurement principles of APB Opinion No. 25, Accounting for Stock Issued to
Employees, and related interpretations. No stock-based
17
employee compensation cost is reflected in net income, as all options granted
under the Company's option plans had an exercise price equal to the market value
of the underlying common stock on the date of grant. The Company determines the
fair value of options issued based on the Black-Scholes model. The Black-Scholes
model is based on certain assumptions including the expected life of the option,
risk free interest rates, expected volatility and expected dividend yield.
Litigation and contingencies
The Company and its subsidiary are from time to time parties to lawsuits
and regulatory administrative proceedings arising out of their respective
operations. The Company records liabilities when a loss is probable and can
reasonably be estimated. The Company believes it has estimated appropriately in
the past; however court decisions and/or other unforeseen events could cause
liabilities to be incurred in excess of estimates.
Contractual Obligations and Commercial Commitments
The following table summarizes contractual obligations and commercial
commitments at March 31, 2004:
================================================================================
PAYMENTS DUE BY PERIOD (in thousands)
----------------------------------------------
Less
CONTRACTUAL than 1 1-3 4-5 After 5
OBLIGATIONS Total year years years years
--------------------------------------------------------------------------------
Operating leases $1,655 $ 486 $1,032 $137 $ --
--------------------------------------------------------------------------------
Employment
agreements * 322 322 -- -- --
--------------------------------------------------------------------------------
Purchase obligations 2,102 1,706 396 -- --
--------------------------------------------------------------------------------
Total Contractual
Cash Obligations $4,079 $2,514 $1,428 $137 $ --
================================================================================
* Two employment agreements with Company executives, the current CEO and former
CEO respectively, are included in this category. Both of these agreements were
terminated in June 2004 upon the resignation of the former CEO and the
appointment of the current CEO. See "Item 11-- Executive Compensation --
Employment Agreements and Termination of Employment Arrangements." In June 2004,
the Company entered into a Consulting and Non-Competition Agreement with its
former CEO, and employment agreements with its current CEO and with its
Executive Vice-President of Sales and Marketing. These agreements provide for
aggregate cumulative payments of $2.5 million, consisting of $724 in fiscal
2005, $932 in fiscal 2006, $741 in fiscal 2007 and $144 in fiscal 2008.
Results Of Operations
The following table sets forth, for the fiscal years indicated, certain
items from the Statement of Operations expressed as a percentage of net
revenues:
Year ended March 31,
2004 2003 2002
------ ------ ------
Revenue, net 100.0% 100.0% 100.0%
------ ------ ------
Cost of sales 28.7% 31.4% 35.0%
Excess and obsolete inventory 0.5% 0.9% 1.2%
------ ------ ------
Total cost of sales 29.2% 32.3% 36.2%
------ ------ ------
Gross profit 70.8% 67.7% 63.8%
Operating expenses:
Selling and marketing 15.5% 19.8% 21.7%
General and administrative 16.0% 16.9% 17.0%
Research and development 8.4% 8.7% 8.9%
Bad debt expense (recovery) 0.3% -- -0.4%
Abandonment of leasehold -- -- 0.5%
------ ------ ------
Total operating costs 40.1% 45.4% 47.7%
------ ------ ------
Operating income 30.7% 22.3% 16.1%
Other income (expense), net 0.3% -0.6% -3.4%
====== ====== ======
Income before tax benefit 30.9% 21.7% 12.7%
====== ====== ======
Income tax benefit, net 15.1% 18.0% --
====== ====== ------
Net income 46.0% 39.7% 12.7%
====== ====== ======
18
Fiscal Year Ended March 31, 2004 as Compared to Fiscal Year Ended March 31, 2003
We design, manufacture and sell innovative digital products for the dental
market. Our primary products are sensors that replace film in the x-ray process.
Growing acceptance of these products have resulted in double-digit revenue
growth in domestic and international markets. In fiscal 2004, we introduced the
first digital wireless sensor and a fully integrated digital panoramic machine.
Continued acceptance of these and other digital product is important to our
success.
During fiscal 2004, Eastman Kodak Company entered the digital dental
market when it acquired PracticeWorks, a practice management company with a
digital sensor manufacturing and marketing subsidiary located in France. The
entry of Kodak into the market did not adversely affect the Company's revenues
or operating margins in fiscal 2004.
Domestic dental product revenues increased 30% to $23.9 million, or 61% of
revenue. Foreign dental product revenues, principally from Europe and Asia,
increased 64% to $9.8 million, or 25% of revenue. Management believes that
continued improvement in the international distribution network and wider
acceptance of the Company's products are the key elements of improving
performance. The pace of our international revenue increase far exceeded the 15%
decline in the value of the U.S. dollar during the year.
Operating expenses, with the exception of legal fees, which are
principally related to the ongoing SEC/US attorney investigation and SEC civil
action, declined as a percent of revenue as the Company leveraged its fixed
expense advantage. After several years of increasingly profitable operations,
the Company has reduced the reserve for deferred income taxes to zero and
recorded a $6.6 million tax benefit at March 31, 2004.
Total revenue increased $9.6 million (32%) to $39.4 million in fiscal 2004
from $29.8 million in fiscal 2003. The revenue increase was due to higher sales
of CDR(R) dental radiography products principally through expansion of sales
through its exclusive domestic distributor, Patterson Dental Company
("Patterson") and through foreign distributors, principally in Europe and Asia.
Total domestic revenues increased $5.8 million (24%) to $29.4 million (75% of
revenue) from $23.6 million (79% of revenue) in fiscal 2003. Total international
revenues increased $3.8 million (62%) to $9.9 million (25% of revenue) from $6.2
million (21% of revenue) in fiscal 2003.
CDR(R) product revenue increased $9.3 million (38%) to $33.7 million (86%
of revenue) during fiscal 2004 from $24.4 million (82% of revenue) during fiscal
2003. AccuDEXA(R) product revenue was unchanged at $0.6 million (1% and 2% of
revenue during fiscal 2004 and fiscal 2003, respectively). Warranty revenues
increased $0.3 million (6%) to $5.1 million (13% of revenue) during fiscal 2004
from $4.8 million (16% of revenue) during fiscal 2003.
19
Patterson revenue amounted to 55% and 52% of total revenue in fiscal 2004
and 2003, respectively. No other individual customer exceeded 10% of total
revenue. Overall sales returns remained under 0.5% of revenue in fiscal 2004 and
2003, respectively.
Total cost of sales for fiscal 2004 increased $1.8 million (19%) to $11.5
million (29% of revenue) from $9.7 million (32% of revenue) in fiscal 2003. The
relative cost of sales declined as a result of the Company's improved operating
efficiency. The Company leveraged fixed overhead over the increase in revenue
while improved product mix resulted in higher margins. Additionally, product
improvements resulted in an overall reduction of expense in support of its
warranty obligations. The Company's provision for excess and obsolete inventory
decreased to 0.5% of net revenue in fiscal 2004 from 0.9% in fiscal 2003.
Selling and marketing expense for fiscal 2004 increased $0.2 million (3%)
to $6.1 million (16% of revenue) from $5.9 million (20% of revenue) in fiscal
2003. Increased sales and sales activities resulted in higher payroll and
commission expenses.
General and administrative expense for fiscal 2004 increased $1.3 million
(25%) to $6.3 million (16% of revenue) from $5.0 million (17% of revenue) in
fiscal 2003. Increases are principally the result of legal fees incurred in
connection with the SEC/US attorney investigation and other corporate business,
other professional fees, a non-cash payroll charge, higher payroll expense,
corporate governance costs and insurance expenses.
Research and development expense in fiscal 2004 increased $0.7 million
(27%) to $3.3 million (8% of revenue) from $2.6 million (9% of revenue) in
fiscal 2003. The increase is the result of higher payroll and research-materials
expenses related to new and ongoing projects.
Interest expense in fiscal 2004 decreased $0.1 million (44%) to $0.2
million from $0.3 million in fiscal 2003 due to the Company's June 2003
prepayment of the outstanding balance of its loan from Greystone. The prepayment
resulted in the write-off of $0.2 million of deferred interest expense in fiscal
2004. Interest income in fiscal 2004 increased $0.1million to $0.2 million as
the Company increased investment in bank certificates of deposit.
During fiscal 2004, the Company reduced its deferred tax valuation
allowance to zero and recorded a $6.6 million income tax benefit. The Company
reduced the valuation allowance because it believes it is more likely than not
that the net operating loss carryforward will be realized. During fiscal 2004,
the Company's utilization of its net operating losses resulted in a reduction of
current taxes in the amount of $4.8 million.
As a result of all of the foregoing items, the Company's net income in
fiscal 2004 increased by $6.3 million (53%) to $18.1 million from $11.8 million
in fiscal 2003.
Fiscal Year Ended March 31, 2003 as Compared to Fiscal Year Ended March 31, 2002
Net revenues increased $5.4 million (22%) to $29.8 million in fiscal 2003
from $24.4 million in fiscal 2002. The revenue increase was due to higher sales
of CDR(R) dental radiography products principally through expansion of sales
through its exclusive domestic distributor, Patterson Dental Company
("Patterson"). Domestic revenues increased $5.3 million (29%) to $23.6 million
(79% of net revenue) from $18.3 million (75% of net revenue) in fiscal 2002.
International sales increased $0.1 million (0.2%) to $6.2 million (21% of net
revenue) from $6.1 million (25% of net revenue) in fiscal 2002.
CDR(R) product sales increased $5.9 million (32%) to $24.4 million (82% of
total revenue) during fiscal 2003 from $18.5 million (76% of total revenue)
during fiscal 2002. AccuDEXA(R) product sales decreased $0.2 million (25%) to
$0.6 million (2% of total revenue) during fiscal 2003 from $0.8 million (3% of
total revenue) during fiscal 2002. Warranty revenues decreased $0.2 million (4%)
to $4.8 million (16% of total revenue) during fiscal 2003 from $5.0 million (21%
of total revenue) during fiscal 2002.
20
Patterson revenue amounted to 52% and 40% of total revenue in fiscal 2003
and 2002, respectively. No other individual customer exceeded 10% of total
revenue. Overall sales returns remained at 0.2% of revenue in fiscal 2003 and
2002.
Total cost of sales for fiscal 2003 increased $0.8 million (9%) to $9.6
million (32% of net revenue) from $8.8 million (36% of net revenue) in fiscal
2002. The decline in relative cost of sales is due to improved operating
efficiency as the Company reduced overhead as a result of the consolidation of
its facilities into a single location during the first quarter of fiscal 2002
and a shift in product sales mix. Additionally, product improvements resulted in
reduced expense in support of its warranty program. The Company's provision for
excess and obsolete inventory decreased to 0.9% of net revenue in fiscal 2003
from 1.2% in fiscal 2002.
Selling and marketing expense for fiscal 2003 increased $0.6 million (12%)
to $5.9 million (20% of net revenue) from $5.3 million (22% of net revenue) in
fiscal 2002. Increased sales and sales activities resulted in higher payroll,
commissions and related travel expenses.
General and administrative expense for fiscal 2003 increased $0.9 million
(22%) to $5.0 million (17% of revenue) from $4.1 million (17% of revenue) in
fiscal 2002. Increases are principally the result of higher payroll, travel and
insurance expenses.
Research and development expense in fiscal 2003 increased $0.4 million
(19%) to $2.6 million (9% of revenue) from $2.2 million (9% of revenue) in
fiscal 2002. The increase is the result of higher payroll and research materials
expenses.
Interest expense in fiscal 2003 decreased $0.7 million (68%) to $0.3
million from $1.0 million in fiscal 2002 due to the Company's July 2001
prepayment of $1 million it had borrowed from Greystone. The prepayment resulted
in the write off of $0.4 million of deferred interest expense in fiscal 2002.
During fiscal 2003, the Company reduced its deferred tax valuation
allowance by $5.8 million resulting in an income tax benefit of $5.5 million,
net of alternative minimum income taxes ("AMT") of $0.3 million. The Company
reduced the valuation allowance because it believes it is more likely than not
that a portion of the net operating loss carryforward will be realized. The
Company continues to reserve approximately $11.1 million of deferred income
taxes. During fiscal 2003, the Company's utilization of its net operating losses
resulted in a reduction of current taxes in the amount of $2.9 million.
As a result of all of the foregoing items, the Company's net income in
fiscal 2003 increased $8.7 million (283%) to $11.8 million from $3.1 million in
fiscal 2002.
Liquidity and Capital Resources
At March 31, 2004, the Company had $20.7 million in cash and cash
equivalents, and working capital of $27.4 million, compared to $7.8 million in
cash and cash equivalents, and $9.2 million in working capital, at March 31,
2003. The increase in working capital is primarily attributable to the Company's
increased operating profit during fiscal 2004.
During fiscal 2004, cash provided by operations was $13.8 million, as
compared to $8.3 million during fiscal 2003. Accounts receivable increased to
$4.0 million at March 31, 2004, as compared to $3.0 million at March 31, 2003,
due to increased sales activity. The allowance for doubtful accounts increased
$96, to $138, at March 31, 2004 from $42 at March 31, 2003, due to a single
account which disputed the amount it owes to the Company. The amount due from
Patterson which was included in accounts receivable ($2.3 million at March 31,
2004) was fully collected after year-end. Inventories increased to $3.1 million
at March 31, 2004, compared to $3.0 million at March 31, 2003. The Company's
capital expenditures
21
decreased to $0.3 million in fiscal 2004 from $0.5 million in fiscal 2003. The
Company's capital expenditures in fiscal 2004 and 2003 primarily consisted of
tooling costs and computer upgrades.
During the fiscal years ended March 31, 2004 and 2003, the Company made
principal payments on long-term debt of $1.5 million and $2.4 million,
respectively. The Company prepaid its long-term debt, in full, in June 2003.
Management believes that its existing capital resources and other
potential sources of credit are adequate to meet its current cash requirements.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet financing arrangements or interests
in so-called special purpose entities.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
None.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The response to this item is included as a separate section of this Annual
Report on Form 10-K, commencing on page F-1.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DATA
None.
ITEM 9A. CONTROLS AND PROCEDURES
a) Under the supervision and with the participation of the Company's
management, including its principal executive officer and its principal
accounting officer, the Company has evaluated the effectiveness of the Company's
disclosure controls and procedures as of March 31, 2004.
They have concluded that these disclosure controls provide reasonable
assurance that the Company can collect, process and disclose, within the time
periods specified in the SEC's rules and forms, the information required to be
disclosed in its periodic Exchange Act reports.
b) There have been no significant changes in the Company's internal
controls or in other factors that could significantly affect its internal
controls subsequent to the date of their most recent evaluation.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
(a) The Directors of the Company are as follows:
Euval Barrekette, Ph.D. Age 73, has served as a Director of the Company
since April 1992 and as a member of the Executive
Compensation Committee of the Board of Directors
since November 2002. Dr. Barrekette's current term
on the Board expires at the Company's Annual
Meeting of Stockholders in 2005. Dr. Barrekette is
a licensed Professional Engineer in New York
State. Since 1986 Dr. Barrekette has been a
consulting engineer and physicist. From
22
1984 to 1986 Dr. Barrekette was Group Director of
Optical Technologies of the IBM Large Systems
Group. From 1960 to 1984 Dr. Barrekette was
employed at IBM's T.J. Watson Research Center in
various capacities, including Assistant Director
of Applied Research, Assistant Director of
Computer Science, Manager of Input/Output
Technologies and Manager of Optics and
Electrooptics. Dr. Barrekette holds an A.B. degree
from Columbia College, a B.S. degree from Columbia
University School of Engineering, an M.S. degree
from its Institute of Flight Structures and a
Ph.D. from the Columbia University Graduate
Faculties. Dr. Barrekette is a fellow of the
American Society of Civil Engineers, a Senior
Member of the Institute of Electrical &
Electronics Engineers, and a member of The
National Society of Professional Engineers, The
New York State Society of Professional Engineers,
The Optical Society of America and The New York
Academy of Science. Dr. Barrekette is the uncle of
David B. Schick, the Company's former Chairman and
Chief Executive Officer, and the brother-in-law of
Dr. Allen Schick.
Jonathan Blank, Esq. Age 59, has served as a Director of the Company
and as a member of the Audit Committee of the
Board of Directors since April 2000, as a member
of the Executive Compensation Committee of the
Board of Directors since November 2002, and as
Chairman of the Special Litigation Committee of
the Board of Directors since September 2003. Mr.
Blank's current term on the Board expires at the
Company's Annual Meeting of Stockholders in 2005.
Since 1979, Mr. Blank has been a member of the law
firm of Preston Gates Ellis & Rouvelas Meeds LLP
and a managing partner of the firm since 1995. Mr.
Blank holds a J.D. degree from Harvard Law School.
William K. Hood Age 80, has served as Chairman of the Board of
Directors since June 2004, as a Director of the
Company and as Chairman of the Audit Committee of
the Board of Directors since February 2002, as a
member of the Executive Compensation Committee of
the Board of Directors since November 2002, and as
a member of the Special Litigation Committee of
the Board of Directors since September 2003. Mr.
Hood's current term on the Board expires at the
Company's Annual Meeting of Stockholders in 2004.
From 1989 to 1996, Mr. Hood served as a consultant
to Harlyn Products, Inc. and as a member of its
Board of Directors. From 1983 to 1988, he was
Senior Vice-President of American Bakeries
Company. From 1981 to 1983, Mr. Hood served as
Dean of the Chapman University School of Business
and Management. From 1972 to 1980, he was
President and Chief Executive Officer of
Hunt-Wesson Foods, Inc. Mr. Hood is currently a
Trustee of Chapman University.
Uri Landesman Age 42, has served as a Director of the Company
since January 2003 and from April 1992 to June
1997, and as a member of the Executive
Compensation and Special Litigation Committees of
the Board of Directors since September 2003. Mr.
Landesman's current term on the Board expires at
the Company's Annual Shareholders Meeting in 2006.
Since January 2004, Mr. Landesman has been a
Senior Vice President and Director of Global
Research at Federated Global Investment Management
Corp. and Senior Portfolio Manager since February
2003. From July 2001 to January 2003, Mr.
Landesman was a Principal and Portfolio Manager at
Arlington Capital Management. From April 1999 to
June 2001, he was a Principal and Chief Investment
Officer at Aaron Fleck & Associates, LLC/A.F.A.
Management Partners, L.P. From June 1993 to March
1999, Mr. Landesman
23
was employed at J.P. Morgan Investment Management,
as Vice-President and Lead Portfolio Manager from
February 1997 to March 1999, and as Vice-President
and Senior Analyst from June 1993 to January 1997.
He holds a B.A. degree from Yeshiva University.
Curtis M. Rocca III Age 41, has served as a Director of the Company
and as a member of the Audit Committee of the
Board of Directors since May 2002, as Chairman of
the Executive Compensation Committee of the Board
of Directors since November 2002, and as a member
of the Special Litigation Committee of the Board
of Directors since September 2003. Mr. Rocca's
current term on the Board expires at the Company's
Annual Meeting of Stockholders in 2004. Since
2000, Mr. Rocca has been the Chief Executive
Officer of Douglas, Curtis & Allyn, LLC. From 1998
to 2000, he served as Chief Executive Officer of
Dental Partners, Inc. From 1990 to 1998, Mr. Rocca
was Chairman and Chief Executive Officer of
Bio-Dental Technologies Corp.
Allen Schick, Ph.D. Age 69, has served as a Director of the Company
since April 1992, and as a member of the Executive
Compensation Committee of the Board of Directors
since November 2002. Dr. Schick's current term on
the Board expires at the Company's Annual Meeting
of Stockholders in 2006. Since 1981, Dr. Schick
has been a professor at the University of Maryland
and, in 2000, was elected "Distinguished
University Professor", a title reserved for fewer
than 2% of the faculty. Since 1988, Dr. Schick has
been a Visiting Fellow at the Brookings
Institution. Dr. Schick holds a Ph.D. degree from
Yale University. Dr. Schick is the father of David
B. Schick, , the Company's former Chairman and
Chief Executive Officer, and the brother-in-law of
Dr. Barrekette.
Jeffrey T. Slovin Age 39, has served as the Company's Chief
Executive Officer since June 15, 2004 and as its
President since December 1999. Mr. Slovin has also
served as a Director of the Company since December
1999. In addition, from November 2001 to June 15,
2004, Mr. Slovin served as the Company's Chief
Operating Officer. Mr. Slovin's current term on
the Board expires at the Company's Annual Meeting
of Stockholders in 2004. Since November 2002, Mr.
Slovin has been a member of the Board of Directors
of Electronic Global Holdings Ltd. From 1999 to
November 2001, Mr. Slovin was a Managing Director
of Greystone & Co., Inc. From 1996 to 1999, Mr.
Slovin served in various executive capacities at
Sommerset Investment Capital LLC, including
Managing Director, and as President of Sommerset
Realty Investment Corp. During 1995, Mr. Slovin
was a Manager at Fidelity Investments Co. From
1991 to 1994, Mr. Slovin was Chief Financial
Officer of Sports Lab USA Corp. and, from 1993 to
1994, was also President of Sports and
Entertainment Inc. From 1987 to 1991, Mr. Slovin
was an associate at Bear Stearns & Co., Inc.,
specializing in mergers and acquisitions and
corporate finance. Mr. Slovin holds an MBA degree
from Harvard Business School.
24
(b) The following table shows the names and ages of all executive officers of
the Company, the positions and offices held by such persons and the period
during which each such person has served as an officer. The term of office of
each person is generally not fixed since each person serves at the discretion of
the Board of Directors of the Company.
Officer
Name Age Position Since
---- --- -------- -----
Jeffrey T. Slovin......... 39 Chief Executive Officer, President 1999
and Director
Michael Stone............. 51 Executive Vice-President of 2000
Sales & Marketing
Stan Mandelkern........... 44 Vice President of Engineering 1999
Ari Neugroschl............ 33 Vice President of Management 2000
Information Systems
Zvi N. Raskin............. 41 Secretary and General Counsel 1992
Will Autz................. 50 Vice President of Manufacturing 2003
Ronald Rosner............. 57 Director of Finance and
Administration 2000
The business experience of each of the executive officers who is not a
Director is set forth below.
MICHAEL STONE has served as the Company's Executive Vice President of Sales and
Marketing since September 2000 and as the Company's Vice President of Sales and
Marketing from January 2000 to September 2000. From September 1993 to January
2000, Mr. Stone was General Manager of the Dental Division of Welch-Allyn
Company, and from October 1989 to September 1993 was Director of Marketing for
Welch-Allyn. Mr. Stone holds an MBA degree from the University of Rochester.
STAN MANDELKERN has served as the Company's Vice President of Engineering since
November 1999. From 1998 to 1999, Mr. Mandelkern was the Company's Director of
Electrical Engineering, and was a Senior Electrical Engineer at the Company from
1997 to 1998. From 1996 to 1997, Mr. Mandelkern was at Satellite Transmission
Systems as Project Leader for the Digital Video Products Group. From 1989 to
1996, Mr. Mandelkern held various design and management positions at Loral Corp.
Mr. Mandelkern holds an M.S. Degree in electrical engineering from Syracuse
University.
ARI NEUGROSCHL has served as the Company's Vice President of Management
Information Systems since July 2000. From November 1997 to July 2000, Mr.
Neugroschl was the Company's Director of Management Information Systems, and
from February 1996 to November 1997 he served as the Company's Director of
Customer Service and Support. Mr. Neugroschl holds a B.S. in Economics from
Yeshiva University.
ZVI N. RASKIN has served as Secretary of the Company since April 1992 and as
General Counsel of the Company since September 1995. From April 1992 to May
1996, Mr. Raskin was a Director of the Company. Mr. Raskin is admitted to
practice law before the Bars of the State of New York, the United States
District Courts for the Southern and Eastern Districts of New York and the
United States Court of Appeals for the Second Circuit. From 1992 to 1995, Mr.
Raskin was a senior associate at the New York law firm of Townley & Updike. Mr.
Raskin holds a J.D. degree from Yale Law School.
WILL AUTZ has served as the Company's Vice President of Manufacturing since
January 2003. From January 2000 to December 2002, Mr. Autz was the Company's
Director of Manufacturing. From 1996 to 1999, Mr. Autz was the Manager of
Manufacturing Engineering at Trident International Inc., a division of Illinois
Tools Work Inc. From 1991 to 1996, Mr. Autz was the Director of Manufacturing &
Manufacturing Engineering at General Signal Networks, a division of General
Signal Inc. Mr. Autz holds a BS in
25
Electromechanical Technology from the New York Institute of Technology and is a
member of the American Society of Manufacturing Engineers.
RONALD ROSNER has served as the Company's Director of Finance and Administration
since August 2000. From March 1999 to August 2000, Mr. Rosner served the Company
in several senior accounting and financial capacities. From October 1998 to
February 1999, Mr. Rosner was a Consultant at Mercantile Ship Corporation, and
from April 1997 to October 1998 was the CFO at Coast MFG. Mr. Rosner holds a
B.S. degree in Accounting from Brooklyn College and has been a Certified Public
Accountant in the State of New York since May 1972. Prior to 1999, for a period
of approximately four years, Mr. Rosner was an audit manager with the
predecessor to Ernst & Young LLP.
(c) Not applicable.
(d) Family Relationships
See Item 10(a).
(e) Business Experience
See Items 10(a) and 10(b).
(f) Involvement in Certain Legal Proceedings
There are no legal proceedings involving any of the Company's Directors or
Officers which are reportable hereunder.
Audit Committee Financial Experts
The Company's Board of Directors has determined that two members of the
Audit Committee, Mr. Hood and Mr. Rocca, are "independent directors" and "audit
committee financial experts," as those terms are defined by the Securities and
Exchange Commission.
Section 16(A) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's executive officers and directors and persons who beneficially own more
than 10% of the Company's Common Stock to file initial reports of ownership and
reports of changes in ownership with the Commission. Such executive officers and
directors and greater than 10% beneficial owners are required by the regulations
of the Commission to furnish the Company with copies of all Section 16(a)
reports they file.
Based solely on a review of the copies of such reports furnished to the
Company and written representations from executive officers and directors, the
Company believes that all Section 16(a) filing requirements applicable to its
executive officers and directors and greater than 10% beneficial owners were
complied with, except that seven Form 5's were filed on May 5, 2004 and one Form
5 was filed on May 11, 2004 for the issuance of employee stock options on
November 3, 2003 by the Board of Directors to the following executive officers,
pursuant to the Company's 1996 Employee Stock Option Plan: Messrs. Mandelkern,
Neugroschl, Raskin, Rosner, David Schick, Slovin, Stone and Autz.
Code of Ethics
On June 2, 2004, by resolution of its Board of Directors, the Company
adopted a code of ethics governing the conduct of Company personnel, including
its principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions. The
code of ethics is filed as Exhibit 14.1 to this Annual Report.
26
In the event that any amendment is made to the code of ethics, and such
amendment is applicable to the Company's principal executive officer, principal
financial officer, principal accounting officer or controller, or persons
performing similar functions, the Company shall disclose the nature of any such
amendment on its Internet website within five business days following the date
of the amendment. In the event that the Company grants a waiver, including an
implicit waiver, from a provision of the code of ethics, to its principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions, the Company shall disclose
the nature of any such waiver, including the name of the person to whom the
waiver is granted and the date of such waiver, on its Internet website within
five business days following the date of the waiver. The Company's Internet
website address is http://www.schicktech.com.
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth certain information concerning compensation
received for the fiscal years ended March 31, 2004, 2003 and 2002 by the
Company's chief executive officer and each of the four most highly compensated
executive officers of the Company whose total salary and other compensation
exceeded $100,000 (the "Named Executives") for services rendered in all
capacities (including service as a director of the Company) during the year
ended March 31, 2004.
Summary Compensation Table
Annual Long-Term
Compensation Compensation Awards
------------ -------------------
Other
Annual Securities All Other
Name and Principal Fiscal Compensa- Underlying Compensa-
Position Year Salary($) Bonus($) tion(1) Options(2) tion($)(3)
----------------------------------------------------------------------------------------------------------
David B. Schick 2004 266,185 100,000 -- 7,379 9,041
Former Chief Executive Officer 2003 246,540 90,463 -- 8,572 6,708
and Former Chairman of the Board 2002 225,246 50,000 -- 160,709 4,362
----------------------------------------------------------------------------------------------------------
Jeffrey T. Slovin 2004 266,378 100,000 -- 7,318 9,690
Chief Executive Officer 2003 246,646 90,463 -- 8,502 6,710
and President 2002 89,430 57,263 -- 150,000 1,846
----------------------------------------------------------------------------------------------------------
Michael Stone 2004 224,700 68,552 -- 6,851 9,335
Executive Vice President of 2003 212,487 45,232 -- 7,439 5,894
Sales and Marketing 2002 193,577 48,154 -- 135,207 4,491
----------------------------------------------------------------------------------------------------------
Zvi N. Raskin, Esq 2004 235,532 13,530 -- 7,111 12,134
General Counsel and 2003 222,690 28,025 -- 7,793 5,078
Secretary 2002 204,154 20,000 -- 36,018 4,527
----------------------------------------------------------------------------------------------------------
Stan Mandelkern 2004 172,895 35,031 -- 6,606 10,195
Vice President of 2003 163,241 5,952 -- 7,240 4,081
Engineering 2002 154,615 -- -- 30,108 3,865
----------------------------------------------------------------------------------------------------------
(1) Does not include other compensation if the aggregate amount thereof does
not exceed the lesser of either $50,000 or 10% of the total annual salary
and bonus for the named officer.
(2) Represents options to purchase shares of Common Stock granted during
fiscal 2004, 2003 and 2002, pursuant to the Company's 1996 Employee Stock
Option Plan.
27
(3) Reflects amounts contributed by the Company in the form of matching
contributions to the Named Executive's Savings Plan account during fiscal
2004, 2003 and 2002.
Employment Agreements and Termination of Employment Arrangements
In May 2004, the Company entered into a Consulting and Non-Competition
Agreement with David Schick, effective upon Mr. Schick's resignation in June
2004 as the Company's Chief Executive Officer and Chairman of the Board. The
Agreement provides for the termination of Mr. Schick's previous Employment
Agreement, described below, and that Mr. Schick is to act as a consultant to the
Company for a period of three years. As a consultant, Mr. Schick will be
responsible for performing certain specified duties, including the exploration
and evaluation of new product ideas and enhancements, evaluating technical
issues relating to potential products or entity acquisitions, conducting
research and development projects, and providing advice with respect to
intellectual property issues. Pursuant to the Agreement, Mr. Schick reports to
the Company's Chief Executive Officer. It also provides that during the term of
the Agreement, and for a period of two years thereafter, Mr. Schick may not
compete with the Company or solicit Company employees, customers or vendors. In
addition, Mr. Schick is required to maintain the confidentiality of the
Company's proprietary information. Pursuant to the Agreement, Mr. Schick is to
be compensated, in full payment for the consulting services to be rendered to
the Company and for his non-competition and other covenants contained in the
Agreement, in the amount of $28,333 per month for a period of 36 months. In
addition, the Agreement provides that 66,307 unvested employee stock options
held by Mr. Schick continue to vest.
In June, 2004, the Company entered into a three-year employment agreement
with Jeffrey T. Slovin. Pursuant to the Agreement, Mr. Slovin is employed as the
Company's Chief Executive Officer and President. Mr. Slovin's annual base salary
is $325,000, $337,000 and $350,000, respectively, during each year of the
initial 3-year term of the Agreement. In addition to base salary, Mr. Slovin is
eligible to receive a yearly bonus payment based on the Company's year-over-year
Earnings-Per-Share growth, as defined in the Agreement. Pursuant to the
Agreement, Mr. Slovin was also awarded 400,000 employee stock options which vest
in equal monthly increments over a period of 48 months. Additionally, under the
Agreement, all Company stock options held by Mr. Slovin will immediately vest in
the event that the Company has a change in control or is acquired by another
company or entity, or, under certain circumstances, if Mr. Slovin is terminated
from employment without cause. In addition, if Mr. Slovin is terminated without
cause, the Agreement provides that he shall receive severance payments equal to
12 months' salary and, if applicable, a pro-rated bonus.
In June, 2004, the Company entered into a two-year employment agreement
with Michael Stone. Pursuant to the Agreement, Mr. Stone is employed as the
Company's Executive Vice President of Sales and Marketing. Mr. Stone's annual
base salary is $250,000 and $260,000, respectively, during each year of the
2-year term of the Agreement. In addition to base salary, Mr. Stone is eligible
to receive a yearly bonus payment based on the Company's year-over-year
Earnings-Per-Share growth, as defined in the Agreement. Pursuant to the
Agreement, Mr. Stone was also awarded 150,000 employee stock options which vest
in equal monthly increments over a period of 48 months. Additionally, under the
Agreement, all Company stock options held by Mr. Stone will immediately vest in
the event that the Company has a change in control or is acquired by another
company or entity, or, under certain circumstances, if Mr. Stone is terminated
from employment without cause. In addition, if Mr. Stone is terminated without
cause, the Agreement provides that he shall receive severance payments equal to
12 months' salary and, if applicable, a pro-rated bonus.
In January 2002, the Company entered into a two-year employment agreement
with Michael Stone, pursuant to which Mr. Stone was employed as the Company's
Executive Vice President of Sales and Marketing. Under the Agreement, Mr.
Stone's annual base salary was $210,000. In addition to base salary, he was
eligible to receive annual merit and/or cost-of-living increases as determined
by the Executive Compensation Committee of the Board of Directors. Pursuant to
the terms of the employment agreement,
28
Mr. Stone also received a performance bonus equal to 0.5% of the Company's
earnings before income taxes, depreciation and amortization for the 2003 fiscal
year. In addition, Mr. Stone received 75,000 employee stock options which vest
as follows: 12,500 options upon grant, an additional 25,000 options on January
14, 2003, an additional 25,000 options on January 14, 2004, and the final 12,500
options on January 14, 2005. The Agreement also provides that all unvested
Company stock options held by Mr. Stone immediately vest in the event that the
Company has a change in control or is acquired by another entity.
In December 2001, the Company entered into a three-year employment
agreement with David Schick, replacing the previous employment agreement between
the Company and Mr. Schick, entered into in February 2000. Pursuant thereto, Mr.
Schick was employed as Chief Executive Officer of the Company until June 2004.
Effective June 15, 2004, Mr. Schick resigned as the Company's Chief Executive
Officer and Chairman of the Board, and his December 2001 employment agreement
was terminated by mutual consent of the parties. Mr. Schick's initial base
annual salary under the Agreement was $242,000. In addition to base salary, Mr.
Schick was eligible to receive annual merit or cost-of-living increases as
determined by the Executive Compensation Committee of the Board of Directors.
Pursuant to the Agreement, Mr. Schick also received an annual increase in base
salary, as well as incentive compensation in the form of a bonus, based on the
Company's EBITDA. Such incentive compensation was capped at $100,000 per fiscal
year. Pursuant to the Agreement, as amended by a letter agreement dated March 4,
2002, Mr. Schick also received 150,000 employee stock options which vest as
follows: 50,000 options on December 20, 2002, an additional 50,000 options on
December 20, 2003, and the final 50,000 options on December 20, 2004.
Additionally, under the Agreement, all Company stock options held by Mr. Schick
will immediately vest in the event that the Company has a change in control or
is acquired by another company or entity.
In November 2001, the Company entered into a three-year employment
agreement with Jeffrey T. Slovin, which was terminated in June 2004 by mutual
consent of the parties, upon the execution of an employment agreement, described
above, pursuant to which Mr. Slovin is employed as the Company's President and
Chief Executive Officer. Pursuant to the Agreement, Mr. Slovin was employed as
President and Chief Operating Officer of the Company until June 2004. Mr.
Slovin's initial base annual salary under the Agreement was $240,000. In
addition to base salary, Mr. Slovin was eligible to receive annual merit or
cost-of-living increases as determined by the Executive Compensation Committee
of the Board of Directors. Pursuant to the Agreement, Mr. Slovin also received
an annual increase in base salary, as well as incentive compensation in the form
of a bonus, based on the Company's EBITDA. Such incentive compensation was
capped at $100,000 per fiscal year. Pursuant to the Agreement, Mr. Slovin also
received 150,000 employee stock options which vest as follows: 50,000 options on
October 31, 2002, an additional 50,000 options on October 31, 2003, and the
final 50,000 options on October 31, 2004. Additionally, under the Agreement, all
Company stock options held by, or issued to, Mr. Slovin immediately vest in the
event that the Company has a change in control or is acquired by another company
or entity.
Compensation of Directors
Directors who are also paid employees of the Company are not separately
compensated for any services they provide as directors. In fiscal 2004, each
director of the Company who was not a paid employee received an annual retainer
of $10,000 as well as $1,000 for each Board meeting attended in person and
$1,000 for each committee meeting attended in person. Each committee chairman
also received an additional annual retainer of $5,000 for each such
chairmanship, and each member of the Audit Committee also received an additional
annual retainer of $5,000. The Company was permitted to, but did not, pay such
fees in Common Stock. Moreover, directors who are not paid employees of the
Company are eligible to receive annual grants of stock options under the
Company's Directors Stock Option Plan.
29
Compensation Committee Interlocks and Insider Participation
The Executive Compensation Committee reviews and makes recommendations
regarding the compensation for top management and key employees of the Company,
including salaries and bonuses. The members of the Executive Compensation
Committee during the fiscal year ended March 31, 2004 were Euval Barrekette,
Jonathan Blank, William K. Hood, Uri Landesman, Curtis M. Rocca, who serves as
Chairman, and Allen Schick. None of such persons is an officer or employee, or
former officer or employee, of the Company or any of its subsidiaries. Allen
Schick and Euval Barrekette are the father and uncle, respectively, of the
Company's former Chief Executive Officer. No interlocking relationship existed
during the fiscal year ended March 31, 2004, between the members of the
Company's Board of Directors or Compensation Committee and the board of
directors or compensation committee of any other company, nor had any such
interlocking relationship existed in the past.
Stock Option Grants
The following table sets forth information regarding grants of options to
purchase Common Stock made by the Company during the year ended March 31, 2004
to each of the Named Executives.
Option Grants in Fiscal 2004
Individual Grants
Number of Percent of
Securities Total Options
Underlying Granted to Exercise
Options Employees in Price Expiration Grant Date
Name Granted(1) Fiscal 2004(2) ($/Share) Date Value (3)
---- ---------- -------------- --------- ---- ---------
David B. Schick 7,379 4.2% $ 8.25 11/4/08 $29,708
Jeffrey T. Slovin 7,318 4.2% $ 7.50 11/4/13 $30,648
Michael Stone 6,851 3.9% $ 7.50 11/4/13 $28,692
Stan Mandelkern 6,606 3.8% $ 7.50 11/4/13 $27,666
Zvi N. Raskin 7,111 4.1% $ 7.50 11/4/13 $29,781
(1) All the options listed in the above table have the following vesting
schedule: 25% shall vest on November 3, 2004, 25% shall vest on November
3, 2005, 25% shall vest on November 3, 2006 and the final 25% shall vest
on November 3, 2007.
(2) The Company granted employees options to purchase a total of 175,000
shares of Common Stock in fiscal 2004.
(3) The Company uses the Black-Scholes valuation model to determine the grant
date value. Assumptions used to calculate the grant date value include:
Volatility 75%
Risk-free interest rate 1.29%
Dividend yield None
Time of exercise 4 years
Option Exercises and Year-End Value Table
The following table sets forth information regarding the exercise of stock
options during fiscal 2004 and the number and value of unexercised options held
at March 31, 2004 by each Named Executive.
30
Aggregated Option Exercises in Fiscal 2004 and Fiscal 2004 Year-End
Option Values
Number of
Securities Value of
Underlying Unexercised
Unexercised "In-the-Money"
Options at Options at
Shares March 31, 2004 March 31, 2004
Acquired on Value Exercisable/ Exercisable/
Name Exercise(#) Realized ($) Unexercisable Unexercisable(1)
---- ----------- ------------ ------------- ----------------
David B. Schick -- -- 109,639/67,021 $916,958/471,524
Jeffrey T. Slovin -- -- 132,125/63,695 $1,180,713/492,713(2)
Michael Stone -- -- 134,003/40,494 $1,205,126/314,543
Stan Mandelkern -- -- 62,609/20,025 $498,560/131,672
Zvi N. Raskin -- -- 30,909/22,512 $101,792/147,864
(1) Options are "in-the-money" if the fair market value of the underlying
securities exceeds the exercise price of the options. The amounts set
forth represent the difference between $10.05 per share, the closing price
per share on March 31, 2004, and the exercise price of the option,
multiplied by the applicable number of options.
(2) This chart does not include warrants issued to Mr. Slovin as designee of
Greystone. Such warrants are discussed in Item 13.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The following table sets forth certain information regarding beneficial
ownership of the Company's Common Stock as of June 10, 2004 by (i) each person
who is known by the Company to own beneficially more than 5% of the Common
Stock, (ii) each director, (iii) each Named Executive of the Company and (iv)
all directors and executive officers of the Company as a group. Unless otherwise
noted, the stockholders listed in the table have sole voting and investment
powers with respect to the shares of Common Stock owned by them.
Number of Shares Percentage of
Name Beneficially Owned (1) Outstanding Shares
----- ---------------------- ------------------
Euval S. Barrekette (2) 178,240(3) 1.2%
Jonathan Blank (4) 190,575(5) 1.3%
Greystone Funding Corp. (6) 4,527,716(7) 30.1%
William K. Hood (8) 60,250(9) *
Uri Landesman (10) 119,600(11) *
Stan Mandelkern (12) 63,609(13) *
Zvi N. Raskin (12) 105,911(14) *
Curtis M. Rocca (15) 32,000(16) *
Allen Schick (17) 653,824(18) 4.3%
David B. Schick (19) 2,292,939(20) 15.1%
Jeffrey T. Slovin (12) 996,292(21) 6.5%
Michael Stone (12) 211,304(22) 1.4%
All current executive Officers
and Directors as a group (23) 4,990,339 31.4%
* Less than 1%
(1) Beneficial ownership is determined in accordance with rules of the
Securities and Exchange Commission and includes voting power and/or
investment power with respect to securities. Shares of
31
Common Stock subject to options or warrants currently exercisable or
exercisable within 60 days of June 10, 2004 are deemed outstanding for
computing the number and the percentage of outstanding shares beneficially
owned by the person holding such options or warrants but are not deemed
outstanding for computing the percentage beneficially owned by any other
person.
(2) Such person's address is 90 Riverside Drive, New York, New York 10024.
(3) Consists of 115,740 shares held by Dr. Barrekette; 2,500 shares issuable
upon the exercise of stock options granted to Dr. Barrekette in July,
1998; 30,000 shares issuable upon the exercise of stock options granted to
Dr. Barrekette in June, 2000, pursuant to the 1997 Directors Stock Option
Plan and 30,000 shares issuable upon the exercise of stock options granted
to Dr. Barrekette in December 2001, pursuant to the 1997 Directors Stock
Option Plan.
(4) Such person's business address is c/o Preston Gates Ellis & Rouvelas Meeds
LLP, 1735 New York Avenue, N.W., Washington, D.C. 20006.
(5) Consists of 130,575 shares held by Mr. Blank; 30,000 shares issuable upon
the exercise of stock options granted to Mr. Blank in June 2000, pursuant
to the 1997 Directors Stock Option Plan and 30,000 shares issuable upon
the exercise of stock options granted to Mr. Blank in December 2001,
pursuant to the 1997 Directors Stock Option Plan.
(6) Greystone's address is 152 West 57th Street, New York, New York 10019.
(7) Consists of 3,975,216 restricted shares issued upon the cashless exercise
of 4,250,000 warrants in March 2004 and 552,500 restricted shares issued
upon the exercise, for cash, of 552,500 warrants in March 2004, all of
which are subject to a registration rights agreement.
(8) Such person's address is 1221 W Coast Highway, Newport Beach, CA 92663.
(9) Consists of 30,250 shares held by Mr. Hood and 30,000 shares issuable upon
the exercise of stock options granted to Mr. Hood in February 2002,
pursuant to the 1997 Directors Stock Option Plan.
(10) Such person's address is 25 Lovell Road, New Rochelle, New York, NY 10804.
(11) Consists of 89,600 shares held by Mr. Landesman and 30,000 shares issuable
upon the exercise of stock options granted to Mr. Landesman in January
2003, pursuant to the 1997 Directors Stock Option Plan.
(12) Such person's business address is c/o Schick Technologies, Inc., 30-00
47th Avenue, Long Island City, New York 11101.
(13) Consists of 1,000 shares held by Mr. Mandelkern; 2,000 shares issuable
upon the exercise of stock options granted to Mr. Mandelkern in April
1998; 5,000 shares issuable upon the exercise of stock options granted to
Mr. Mandelkern in July 1998; 2,560 shares issuable upon the exercise of
stock options granted to Mr. Mandelkern in March 1999; 29,120 shares
issuable upon the exercise of stock options granted to Mr. Mandelkern in
January 2000; 15,660 shares issuable upon the exercise of stock options
granted to Mr. Mandelkern in January 2001; 6,459 shares issuable upon the
exercise of stock options granted to Mr. Mandelkern in October 2001 and
1,810 shares issuable upon the exercise of stock options granted to Mr.
Mandelkern in November 2002.
(14) Consists of 75,000 shares (the "Shares") issued by the Company to Mr.
Raskin on February 6, 2000, which were subject to restrictions on their
sale or transfer which have expired; 2,343 shares issuable upon the
exercise of stock options granted to Mr. Raskin in July 1997; 2006 shares
issuable upon the exercise of options granted to Mr. Raskin in April 1998;
5,000 shares issuable upon the exercise of
32
options granted to Mr. Raskin in July 1998; 10,000 shares issuable upon
the exercise of options granted to Mr. Raskin in October 1998, 3,313
shares issuable upon the exercise of options granted to Mr. Raskin in
October 2001; 6,300 shares issuable upon the exercise of stock options
granted to Mr. Raskin in December 2001 and 1,949 shares issuable upon the
exercise of options granted to Mr. Raskin in November 2002.
(15) Such person's business address is c/o Douglas, Curtis & Allyn, LLC, 2998
Douglas Boulevard, Suite 300, Roseville, CA 95661.
(16) Consists of 2,000 shares held by Mr. Rocca and 30,000 shares issuable upon
the exercise of stock options granted to Mr. Rocca in July 2002, pursuant
to the 1997 Directors Stock Option Plan.
(17) Such person's business address is University of Maryland at College Park,
School of Public Affairs, Van Munching Hall, College Park, Maryland
20742-182190.
(18) Consists of 546,524 shares held jointly by Dr. Schick and his wife; 44,800
shares held by Dr. Schick as custodian for the minor children of David
Schick; 2,500 shares issuable upon the exercise of stock options granted
to Dr. Schick in July 1998; 30,000 shares issuable upon the exercise of
stock options granted to Dr. Schick in June, 2000, pursuant to the 1997
Directors Stock Option Plan and 30,000 shares issuable upon the exercise
of stock options granted to Dr. Schick in December 2001, pursuant to the
1997 Directors Stock Option Plan. Dr. Schick disclaims beneficial
ownership of the 44,800 shares held as custodian.
(19) Such person's address is 147-48 69th Road, Flushing, New York 11367.
(20) Consists of 1,104,150 shares held by Mr. Schick and 1,079,150 shares held
by his wife; 7,496 shares issuable upon the exercise of stock options
granted to Mr. Schick in October 2001; 50,000 shares issuable upon the
exercise of stock options granted to Mr. Schick in December 2001; 50,000
shares issuable upon the exercise of stock options granted to Mr. Schick
in February 2002 and 2,143 shares issuable upon the exercise of stock
options granted to Mr. Schick in November 2002.
(21) Consists of 847,500 shares issuable upon the exercise of warrants held by
Mr. Slovin (which he received as designee of Greystone); 100,000 shares
issuable upon the exercise of stock options granted to Mr. Slovin in
November 2001; 2,126 shares issuable upon the exercise of stock options
granted to Mr. Slovin in November 2002; 16,666 shares issuable upon the
exercise of stock options granted to Mr. Slovin in June 2004;and 30,000
shares issuable upon the exercise of stock options granted to Mr. Slovin
in June 2000, pursuant to the 1997 Directors Stock Option Plan.
(22) Consists of 71,050 shares held by Mr. Stone; 25,000 shares issuable upon
the exercise of stock options granted to Mr. Stone in January 2000; 18,750
shares issuable upon the exercise of stock options granted to Mr. Stone in
January 2001; 18,750 shares issuable upon the exercise of stock options
granted to Mr. Stone in December 2001; 7,144 shares issuable upon the
exercise of stock options granted to Mr. Stone in October 2001; 62,500
shares issuable upon the exercise of stock options granted to Mr. Stone in
January 2002; 1,860 shares issuable upon the exercise of stock options
granted to Mr. Stone in November 2002 and 6,250 shares issuable upon the
exercise of stock options granted to Mr. Stone in June 2004.
(23) Includes the shares underlying warrants described in Note 21 as well as
shares subject to options held by current officers and directors.
A table containing information, as of March 31, 2004, with respect to
compensation plans (including individual compensation arrangements) under which
equity securities of the Company are authorized for issuance is set forth above.
See "Item 5 -- Market for Registrant's Common Equity and Related Stockholder
Matters -- Equity Compensation Plan Information."
33
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
In 1999, in connection with a Loan Agreement with Greystone, the Company
issued to Greystone 4,250,000 warrants to purchase the Company's Common Stock,
and to Jeffrey T. Slovin, as Greystone's designee, 750,000 warrants to purchase
the Company's Common Stock. Mr. Slovin is the Company's Chief Executive Officer
and President, pursuant to a written employment agreement, and serves as a
Director of the Company. See "Item 11--Executive Compensation -- Employment
Agreements and Termination of Employment Arrangements."
On July 5, 2001, the Company repaid all outstanding advances under the
Greystone amended Loan Agreement, together with all unpaid accrued interest
thereunder, and concurrently terminated said amended Loan Agreement. On July 12,
2001, the Company and Greystone entered into a Termination Agreement, effective
as of March 31, 2001, acknowledging the repayment and termination of the amended
Loan Agreement and agreeing that all the Company's obligations thereunder have
been fully satisfied. The Company and Greystone further agreed, among other
matters, that: (i) five million warrants held by Greystone and its assigns to
purchase Common Stock of the Company remained in full force and effect; (ii) the
Registration Rights Agreement between Greystone and the Company dated as of
December 27, 1999 remains in full force and effect; and (iii) for so long as
Jeffrey T. Slovin held the office of President of the Company, the Company shall
reimburse Greystone in the amount of $17 monthly. Effective November 1, 2001,
Mr. Slovin joined the Company on a full-time basis and left the employ of
Greystone, thereby canceling this reimbursement provision of the agreement.
In addition, in 1999, DVI Financial Services, Inc. ("DVI") provided the
Company with notes payable for $6.6 million, secured by first priority liens on
substantially all of the Company's assets. See "Item 7 -- Management's
Discussion and Analysis -- Liquidity and Capital Resources." Effective August
28, 2000, DVI transferred its rights, title and interest in, to, and under the
DVI Notes payable and related loan documents to Greystone. In connection with
such transfer, DVI directed the Company to make all remaining payments due under
the loan documents to Greystone. Concurrently, DVI transferred 650,000 warrants
to purchase the Company's Common Stock to Greystone, of which 97,500 warrants
were transferred to Mr. Slovin, as Greystone's designee.
During the first quarter of fiscal 2004, the Company prepaid to Greystone
$396 of outstanding principal of the DVI loan. The April 2003 prepayment
constituted full satisfaction of the Company's obligations to Greystone for the
period through March 31, 2003, pursuant to an Amendment and Waiver Agreement
between the Company and Greystone entered into in March 2003. The loan was
repaid in full on June 30, 2003.
In March 2004, Greystone exercised all of its outstanding warrants. In one
transaction Greystone paid $414,000 to acquire 552,500 unregistered shares of
common stock. In a second transaction Greystone exercised pursuant to the
cashless provisions of its grant of 4,250,000 warrants and received, as a
result, 3,975,216 unregistered shares of common stock. The market price of the
Company's Common Stock was $11.60 at the date of exercise. The shares acquired
by Greystone remain subject to registration rights agreements pursuant to which
Greystone may demand that the Company register such shares for resale.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Audit Fees
The aggregate fees billed by our auditors to date, for professional
services rendered for the audit of the Company's annual financial statements for
the years ended March 31, 2004 and March 31, 2003, and for review of the
financial statements included in the Company's quarterly reports on Form 10-Q
during those fiscal years were $ 249,258 and $ 233,103, respectively.
34
Audit-Related Fees
For the year ended March 31, 2004, the aggregate fees billed for assurance
and related services by our auditors that are reasonably related to the
performance of the audit or review of our financial statements were $9,210,
relating to other services traditionally performed by independent accountants;
no such fees were billed for the year ended March 31, 2003.
Tax Fees
Fees billed by our auditors for the preparation of corporate income tax
returns were $29,380 and $16,250 for the years ended March 31, 2004 and 2003,
respectively.
All Other Fees
For the fiscal years ended March 31, 2004 and 2003, there were no fees
incurred by the Company for services rendered by the auditors to the Company,
other than the services reported above, in "Audit Fees," "Audit-Related Fees"
and "Tax Fees."
Pre-Approval Policies and Procedures
Prior to engaging our accountants to perform a particular service, our
Board of Directors obtains an estimate for the service to be performed. The
Audit Committee, in accordance with Company procedures and pursuant to its
Charter, approved all of the services described above.
35
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
SCHICK TECHNOLOGIES, INC.
Index to Consolidated Financial Statements F-1
Report of Independent Registered Public Accounting Firm F-2
Consolidated Balance Sheets as of March 31, 2004 and 2003 F-3
Consolidated Statements of Operations for the years ended
March 31, 2004, 2003 and 2002 F-4
Consolidated Statements of Changes in Stockholders' Equity
for the years ended March 31, 2004, 2003 and 2002 F-5
Consolidated Statements of Cash Flows for the years ended
March 31, 2004, 2003 and 2002 F-6
Notes to Consolidated Financial Statements F-7
Schedule II/Valuation and Qualifying Accounts F-22
F-1
Report of Independent Registered Public Accounting Firm
To the Board of Directors
and Stockholders of Schick Technologies, Inc.
We have audited the accompanying consolidated balance sheets of Schick
Technologies, Inc. and subsidiary (the "Company") as of March 31, 2004 and 2003,
and the related consolidated statements of operations, changes in stockholders'
equity (deficiency) and cash flows for each of the three years in the period
ended March 31, 2004. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards of the Public
Accounting Company Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of Schick
Technologies, Inc. and subsidiary as of March 31, 2004 and 2003, and the
consolidated results of their operations and their consolidated cash flows for
each of the three years in the period ended March 31, 2004, in conformity with
accounting principles generally accepted in the United States of America.
As discussed in Note 4 of the consolidated financial statements, effective April
1, 2002, the Company changed its method for accounting for goodwill and
intangible assets upon the adoption of Statement of Accounting Standards 142,
"Goodwill and Other Intangible Assets".
We have also audited Schedule II -- Valuation and Qualifying Accounts of Schick
Technologies, Inc. and subsidiary for each of the three years in the period
ended March 31, 2004. In our opinion, this schedule presents fairly, in all
material respects, the information required to be set forth therein.
/s/ GRANT THORNTON LLP
New York, New York
May 14, 2004,
except for Note 18 and the first paragraph of Note 14, as to which the date is
June 10, 2004
F-2
Schick Technologies, Inc. and Subsidiary
Consolidated Balance Sheets
(In thousands, except share amounts)
*
March 31,
---------
2004 2003
-------- --------
Assets
Current assets
Cash and cash equivalents $ 20,734 $ 7,100
Short-term investments -- 712
Accounts receivable, net of allowance for doubtful accounts of $138 and
and $42, respectively 3,982 3,032
Inventories 3,057 3,039
Income taxes receivable 5 10
Prepayments and other current assets 856 421
Deferred income taxes 6,481 2,590
-------- --------
Total current assets 35,115 16,904
-------- --------
Equipment, net 1,405 2,151
Goodwill, net 266 266
Deferred income taxes 5,679 2,940
Other assets 278 349
-------- --------
Total assets $ 42,743 $ 22,610
======== ========
Liabilities and Stockholders' Equity
Current liabilities
Current maturity of long-term debt $ -- $ 1,503
Accounts payable and accrued expenses 1,456 1,468
Accrued salaries and commissions 1,390 1,080
Income taxes payable 142 4
Deposits from customers 13 31
Warranty obligations 210 56
Deferred revenue 4,504 3,605
-------- --------
Total current liabilities 7,715 7,747
-------- --------
Commitments and contingencies -- --
Stockholders' equity
Preferred stock ($0.01 par value; 2,500,000
shares authorized; none issued and outstanding) -- --
Common stock ($0.01 par value; 50,000,000 shares authorized:
15,026,470 and 10,206,425 shares issued and outstanding,
at March 31, 2004 and 2003, respectively) 150 102
Additional paid-in capital 44,626 42,618
(Accumulated deficit) (9,748) (27,857)
-------- --------
Total stockholders' equity 35,028 14,863
-------- --------
Total liabilities and stockholders' equity $ 42,743 $ 22,610
======== ========
----------
* The accompanying notes are an integral part of these financial statements
F-3
Schick Technologies, Inc. and Subsidiary
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
*
Year ended March 31,
2004 2003 2002
------------ ------------ ------------
Revenue, net $ 39,393 $ 29,817 $ 24,399
------------ ------------ ------------
Cost of sales 11,310 9,369 8,540
Excess and obsolete inventory 185 259 292
------------ ------------ ------------
Total cost of sales 11,495 9,628 8,832
------------ ------------ ------------
Gross profit 27,898 20,189 15,567
------------ ------------ ------------
Operating expenses:
Selling and marketing 6,118 5,911 5,291
General and administrative 6,291 5,041 4,148
Research and development 3,301 2,598 2,176
Bad debt expense (recovery) 105 -- (93)
Lease termination -- -- 118
------------ ------------ ------------
Total operating expenses 15,815 13,550 11,640
------------ ------------ ------------
Income from operations 12,083 6,639 3,927
------------ ------------ ------------
Other income (expense)
Other income 138 51 140
Gain on sale of investment -- 45 --
Interest income 153 52 33
Interest expense (182) (322) (1,012)
------------ ------------ ------------
Total interest and other income (expense) 109 (174) (839)
------------ ------------ ------------
Income before income taxes 12,192 6,465 3,088
Income tax benefit 5,917 5,360 --
------------ ------------ ------------
Net income $ 18,109 $ 11,825 $ 3,088
============ ============ ============
Basic earnings per share $ 1.69 $ 1.17 $ 0.30
============ ============ ============
Diluted earnings per share $ 1.07 $ 0.78 $ 0.26
============ ============ ============
Weighted average common shares (basic) 10,710,742 10,148,991 10,137,209
============ ============ ============
Weighted average common shares (diluted) 16,864,488 15,143,999 11,915,351
============ ============ ============
----------
* The accompanying notes are an integral part of these financial statements
F-4
Schick Technologies, Inc. and Subsidiary
Consolidated Statements of Changes in Stockholders' Equity (Deficiency)
(In thousands, except share amounts)
*
(Accumulated Total
Common Stock Additional Deficit) Stockholders'
------------------------- Paid -in Retained Equity
Shares Amount Capital Earnings (Deficiency)
---------- ---------- ---------- ---------- ----------
Balance at March 31, 2001 10,137,149 101 $ 42,480 $ (42,770) $ (189)
Issuance of common stock 1,176 -- 1 -- 1
Net profit -- -- -- 3,088 3,088
---------- ---------- ---------- ---------- ----------
Balance at March 31, 2002 10,138,325 101 42,481 (39,682) 2,900
Issuance of common stock 68,100 1 62 -- 63
Tax benefit of stock options exercised 75 75
Net profit -- -- -- 11,825 11,825
---------- ---------- ---------- ---------- ----------
Balance at March 31, 2003 10,206,425 102 42,618 (27,857) 14,863
Issuance of common stock 4,820,045 48 790 -- 838
Tax benefit of stock options exercised 463 463
Appreciation of variable stock grant 655 655
Other -- -- 100 -- 100
Net profit -- -- -- 18,109 18,109
---------- ---------- ---------- ---------- ----------
Balance at March 31, 2004 15,026,470 150 $ 44,626 $ (9,748) $ 35,028
========== ========== ========== ========== ==========
----------
* The accompanying notes are an integral part of these financial statements
F-5
Schick Technologies, Inc. and Subsidiary
Consolidated Statements of Cash Flows
*(In thousands)
Year ended March 31,
2004 2003 2002
-------- -------- --------
Cash flows from operating activities
Net income $ 18,109 $ 11,825 $ 3,088
Adjustments to reconcile net income to
net cash provided by operating activities
Deferred tax asset (6,630) (5,530) --
Tax benefit of stock options exercised 463 75 --
Depreciation and amortization 1,063 1,289 1,527
Gain from repayment of long-term debt (50) -- --
Provision for (recovery of) bad debts 105 -- (93)
Provisions for excess and obsolete inventory 185 259 292
Amortization of deferred finance charge 150 135 169
Gain on sale of investment -- (45) --
Interest accretion -- -- 365
Non-cash compensation 433 222 --
Other -- 150 (51)
Changes in assets and liabilities:
Accounts receivable (1,055) (220) (1,742)
Inventories (203) (493) 723
Prepayments and other current assets (430) (115) (91)
Other assets (103) (58) (15)
Accounts payable and accrued expenses 620 804 (626)
Income taxes payable 138 4 --
Deposits from customers (43) 1 (453)
Warranty obligations 179 (16) (69)
Deferred revenue 899 26 447
-------- -------- --------
Net cash provided by operating activities 13,830 8,313 3,471
-------- -------- --------
Cash flows from investing activities
Proceeds of short-term investments 712 431 5
Purchase of short-term investments -- (671) (417)
Proceeds from sale of investment -- 169 662
Capital expenditures, net (292) (476) (825)
-------- -------- --------
Net cash provided by (used in) investing activities 420 (547) (575)
-------- -------- --------
Cash flows from financing activities
Issuance of common stock 837 63 1
Payment of long-term debt (1,453) (2,351) (3,442)
-------- -------- --------
Net cash used in financing activities (616) (2,288) (3,441)
-------- -------- --------
Net increase (decrease) in cash and cash equivalents 13,634 5,478 (545)
Cash and cash equivalents at beginning of period 7,100 1,622 2,167
-------- -------- --------
Cash and cash equivalents at end of period $ 20,734 $ 7,100 $ 1,622
======== ======== ========
Interest paid $ 32 $ 196 $ 955
======== ======== ========
Income taxes paid $ 111 $ 91 $ --
======== ======== ========
In March 2004, the Company's former lender exercised 4,802,500 warrants
and the Company issued 4,527,716 unregistered shares of common stock.
----------
* The accompanying notes are an integral part of these financial statements
F-6
Schick Technologies, Inc. and Subsidiary
Notes to Consolidated Financial Statements
(Amounts In thousands, except share and per share amounts)
1. Organization and Business
Schick Technologies, Inc. (the "Company") designs, develops, manufactures
and markets innovative digital radiographic imaging systems and devices for the
dental and medical markets that utilize low dosage radiation to produce instant
computer generated, high-resolution, electronic x-ray images. The Company's
products are sold worldwide.
The Company operates in one reportable segment -- digital radiographic
imaging systems. The Company's principal products include the CDR(R) computed
digital radiography imaging system and the accuDEXA(R) bone densitometer.
The following is a summary of the Company's revenues from its principal
products (including warranty revenue relating to each respective product):
% Of Total Revenue
2004 2003 2002
---- ---- ----
CDR(R) 98% 98% 97%
AccuDEXA(R) 2% 2% 3%
--- --- ---
100% 100% 100%
=== === ===
2. Summary of Significant Accounting Policies
Basis of Consolidation
The accompanying consolidated financial statements include the accounts of
the Company and its wholly owned subsidiary, Schick New York. All material
intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. These estimates and assumptions relate to
the allowance for doubtful accounts, allowances for estimated sales returns,
estimated costs of initial warranties, and the valuation allowance on deferred
tax assets. Management has exercised reasonable judgment in deriving these
estimates. However, actual results could differ from these estimates.
Consequently, an adverse change in conditions could affect the Company's
estimates.
Cash Equivalents
Cash equivalents consist of short-term, highly liquid investments, with
original maturities of less than three months when purchased and are stated at
cost. At March 31, 2004, cash balances in excess of FDIC insurance approximates
$20.5 million.
F-7
Short-Term Investments
Investments with original maturities greater than three months and less
than one year when purchased are classified as short-term investments.
Investments are categorized as held-to-maturity and are carried at amortized
cost, without recognition of gains or losses that are deemed to be temporary, as
the Company has both the intent and the ability to hold these investments until
they mature.
Accounts Receivable
The Company reports accounts receivable net of reserves for uncollectible
accounts. The majority of the Company's accounts receivable (58% and 62%, at
March 31, 2004 and 2003, respectively) are due from its exclusive domestic
distributor, Patterson Dental Company ("Patterson"). Other accounts receivable
are due from international distributors and agencies of the US military. Credit
is extended to distributors on varying terms between 30 and 90 days. Most
international credit is underwritten by credit insurance. The Company provides
an allowance for doubtful accounts based upon analysis of the accounts
receivable aging. The Company writes off accounts receivable when they become
uncollectible. Subsequently received payments are credited to operations.
Inventories
Inventories are stated at the lower of cost (determined on a first-in,
first-out basis) or market value. Cost is determined principally on the standard
cost method for manufactured goods and on the average cost method for other
inventories, each of which approximates actual cost on the first-in, first-out
method. The Company establishes reserves for inventory estimated to be obsolete,
unmarketable or slow moving inventory equal to the difference between the cost
of inventory and estimated market value based upon assumptions about future
demand and market conditions. If actual market conditions are less favorable
than those anticipated or if changes in technology affect the Company's
products, additional inventory reserves may be required.
Equipment
Equipment is stated at cost. The cost of additions and substantial
improvements to equipment is capitalized. The cost of maintenance and repairs of
equipment is charged to operating expenses. Depreciation and amortization are
provided on the straight-line method over the lesser of the estimated useful
lives of the related assets ranging from five to ten years or, where
appropriate, the lease term.
Revenue Recognition
The Company recognizes revenue when each of the following four criteria is
met: 1) a contract or sales arrangement exists; 2) products have been shipped
and title has been transferred or services have been rendered; 3) the price of
the products or services is fixed or determinable; and 4) collectibility is
reasonably assured. Revenues from sales of the Company's hardware and software
products are recognized at the time of shipment to customers, and when no
significant obligations exist and collectibility is probable. The Company
provides its exclusive domestic distributor with a 30-day return policy but
allows for an additional 15 days, and accordingly recognizes allowances for
estimated returns pursuant to such policy at the time of shipment. Revenue from
shipments to foreign customers is recognized at the time of shipment in
accordance with foreign sales orders. With respect to products shipped to its
exclusive domestic distributor, the Company defers revenue until Patterson ships
such inventory from its distribution centers. Amounts received from customers in
advance of product shipment are classified as deposits from customers. The
Company records as revenue shipping and handling charges invoiced to customers.
The cost of shipping and handling is recorded in cost of sales. Revenues from
the sale of extended warranties on the Company's products are recognized on a
straight-line basis over the life of the extended warranty, which is generally a
one-year period. Deferred revenues relate to extended warranty fees paid by
customers prior to the performance of extended warranty services, to certain
shipments to Patterson, as described above, and to the 90-day exchange program
for CDR(R) wireless, as follows: Patterson instituted a policy permitting, under
specific circumstances, the exchange of CDR(R) wireless products, sold after
October 23, 2003, for wired CDR(R) products. This exchange is allowed for a
period of 90 days from the date of installation in the event that external
radio-frequency sources cause interference that cannot be resolved.
F-8
Accordingly, the Company has deferred recognition of revenue related to
Patterson's shipment of the CDR(R) wireless product until the foregoing 90-day
period has elapsed.
Advertising Costs
Advertising costs included in selling and marketing expenses are expensed
as incurred and were $437, $568 and $492, for the years ended March 31, 2004,
2003, and 2002, respectively.
Warranties
The Company records a liability for an estimate of costs that it expects
to incur under its basic limited warranty when product revenue is recognized.
Factors affecting the Company's warranty liability include the number of units
sold and historical and anticipated rates of claims and costs per claim. The
Company periodically assesses the adequacy of its warranty liability based on
changes in these factors.
The Company records revenues on extended warranties on a straight-line
basis over the term of the related warranty contracts (generally one year).
Deferred revenues related to extended warranty were $2.4 million and $2.3
million at March 31, 2004 and 2003, respectively. Services costs are expensed as
incurred.
Research and Development
Research and development costs consist of expenditures covering basic
scientific research and the application of scientific advances to the
development of new and improved products and their uses. Research and
development costs are expensed as incurred. Software development costs for
external use software incurred after the establishment of technological
feasibility are capitalized and amortized to cost of revenues on a straight-line
basis over the expected useful life of the software. Software development costs
incurred prior to the attainment of technological feasibility are considered
research and development and are expensed as incurred. Costs of software
developed for internal use incurred during the development of the application
are capitalized and amortized to operating expense on a straight-line basis over
the expected useful life of the software. The Company did not capitalize any
software development costs during 2004, 2003 and 2002.
Income Taxes
Income taxes are accounted for under the asset and liability method.
Deferred income taxes are recorded for temporary differences between financial
statement carrying amounts and the tax basis of assets and liabilities. Deferred
tax assets and liabilities reflect the tax rates expected to be in effect for
the years in which the differences are expected to reverse. A valuation
allowance is provided if it is more likely than not that some or the entire
deferred tax asset will not be realized.
Fair Value of Financial Instruments
The carrying value of cash and cash equivalents, accounts receivable,
accounts payable and debt approximates fair value due to the relatively short
maturity associated with the Company's cash, accounts receivable and accounts
payable and the interest rates associated with its debt.
Goodwill and Other Intangible Assets
Goodwill represents the cost of acquired companies in excess of the fair
value of the net assets acquired. At the date of acquisition, goodwill is
allocated to reporting units based on net assets assigned to that unit.
Effective April 1, 2002, the Company adopted Statement of Financial Accounting
Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets", which
established financial accounting and reporting for acquired goodwill and other
intangible assets and superseded Accounting Principles Board Opinion ("APB") No.
17, "Intangible Assets". Under SFAS No. 142 goodwill and indefinite-lived
purchased intangible assets are no longer amortized but are reviewed at least
annually for impairment. The Company has elected to perform this review annually
as of February 28.
F-9
Identifiable intangible assets that have finite lives continue to be
amortized over their estimated useful lives. Other intangible assets include
costs incurred to secure patents and deferred financing costs, and are included
in other assets. Finite-lived purchased intangible assets are amortized
principally by the straight-line method over their expected period of benefit.
Costs incurred to secure patents and deferred financing costs are amortized by
the straight-line method over periods of five years and over the term of the
loan, respectively.
Long-lived assets and intangibles are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability of assets to be held and used is measured
by a comparison of the carrying amount of the assets to the future net cash
flows expected to be generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the assets exceeds the fair value of the assets.
Stock-based compensation
At March 31, 2004, the Company has stock-based compensation plans which
are described more fully in Note 14. As permitted by SFAS No. 123, "Accounting
for Stock Based Compensation", the Company accounts for stock-based compensation
arrangements with employees under the recognition and measurement principles of
APB Opinion No. 25, "Accounting for Stock Issued to Employees, and related
Interpretations". No stock-based employee compensation cost is reflected in net
income, as all options granted under those plans had an exercise price equal to
the market value of the underlying common stock on the date of grant. The
following table illustrates the effect on net income and earnings per share if
the Company had applied the fair value recognition provisions of FASB Statement
No. 123, Accounting for Stock-Based Compensation, to stock-based employee
compensation.
Year ended March 31,
2004 2003 2002
---------- ---------- ----------
Net income, as reported $ 18,109 $ 11,825 $ 3,088
Deduct: Total stock-based employee compensation
expense determined under fair value based method for
all awards, net of related tax effects 359 476 474
---------- ---------- ----------
Pro forma net income $ 17,750 $ 11,349 $ 2,614
---------- ---------- ----------
Earnings per share:
Basic-as reported $ 1.69 $ 1.17 $ 0.30
---------- ---------- ----------
Basic-pro forma $ 1.66 $ 1.12 $ 0.26
---------- ---------- ----------
Diluted-as reported $ 1.07 $ 0.78 $ 0.26
---------- ---------- ----------
Diluted-pro forma $ 1.05 $ 0.75 $ 0.22
---------- ---------- ----------
Reclassifications
Certain reclassifications have been made to the prior years' financial
statements to conform to the current presentation.
3. Recently Issued Accounting Standards
Revenue Recognition
In November 2002, the Emerging Issues Task Force reached a consensus
opinion of EITF 00-21, "Revenue Arrangements with Multiple Deliverables". That
consensus provides that revenue arrangements with multiple deliverables should
be divided into separate units of accounting if certain criteria are met. The
consideration of the arrangement should be allocated to the separate units of
accounting based on their relative fair values, with different provisions if the
fair value of all deliverables are not known or if the fair
F-10
value is contingent on delivery of specified items or performance conditions.
Applicable revenue criteria should be considered separately for each separate
unit of accounting. EITF 00-21 was effective for revenue arrangements entered
into in fiscal periods beginning after June 15, 2003. Entities may elect to
report the change as a cumulative effect adjustment in accordance with APB
Opinion 20, "Accounting Changes." The adoption of EITF 00-21 did not have a
material impact on the Company's consolidated financial position, results of
operations or cash flows.
Accounting for Certain Financial Instruments
In May 2003, the Financial Accounting Standards Board (FASB) issued
SFAS150, "Accounting for Certain Financial Instruments with Characteristic of
both Liabilities and Equity". It requires that an issuer classify a financial
instrument that is within its scope as a liability (or an asset in some
circumstances). This Statement is effective for financial instruments entered
into or modified after May 31, 2003 (except for mandatorily redeemable
noncontrolling interests). For all instruments that existed prior to May 31,
2003, SFAS 150 is effective at the beginning of the first interim period
beginning after June 15, 2003 (except for mandatorily redeemable noncontrolling
interests). For mandatorily redeemable noncontrolling interests, the FASB has
deferred certain provisions of SFAS 150. The adoption of SFAS 150 did not have a
material effect on our consolidated financial position, results of operations or
cash flows.
Variable Interest Entities
In January 2003, the FASB issued FASB Interpretation ("FIN") No. 46,
"Consolidation of Variable Interest Entities," as amended by FIN No. 46(R) in
December 2003. FIN 46(R) requires certain variable interest entities to be
consolidated by the primary beneficiary if the entity does not effectively
disperse risk among the parties involved. The provisions of FIN No. 46(R) are
effective immediately for those variable interest entities created after January
31, 2003. The provisions were effective for the quarter ended September 30, 2003
for those variable interest entities held prior to February 1, 2003. The Company
does not currently have any variable interest entities as defined in FIN No.
46(R). Consequently, the adoption of FIN No. 46(R) had no material impact on the
Company's results of operations, financial position or cash flows.
4. Accounting for Business Combinations, Intangible Assets and Goodwill
In July 2001, the Financial Accounting Standards Board issued SFAS No.
141, "Business Combinations" and SFAS 142, "Goodwill and Other Intangible
Assets". The new standards require that all business combinations initiated
after June 30, 2001 must be accounted for under the purchase method. In
addition, all intangible assets acquired that are obtained through contractual
or legal right, or are capable of being separately sold, transferred, licensed,
rented or exchanged, shall be recognized as assets apart from goodwill. Goodwill
and intangibles with indefinite lives will no longer be subject to amortization,
but will be subject to at least an annual assessment for impairment by applying
a fair value based test.
The Company continued to amortize under its then current method until
March 31, 2002. Thereafter, annual goodwill amortization of $107 is no longer
recognized. In August 2002, the Company performed a transitional fair value
based impairment test and in, March 2004 and 2003, performed annual fair value
impairment tests. These tests indicate that the fair value is greater than the
recorded value of goodwill. Therefore the Company's goodwill was not impaired
during the year ended March 31, 2004 and 2003.
The adjustment of previously reported net income and earnings per share
represents the recorded amortization of goodwill. The impact on net income and
basic and diluted earnings per share for the years ended March 31, 2004, 2003
and 2002 are set forth below:
Year ended March 31
2004 2003 2002
----------- ----------- -----------
Reported net income $ 18,109 $ 11,825 $ 3,088
Add back of goodwill amortization -- -- 107
----------- ----------- -----------
Adjusted net income $ 18,109 $ 11,825 $ 3,195
=========== =========== ===========
Basic and diluted earnings per share:
Basic net income $ 1.69 $ 1.17 $ 0.30
=========== =========== ===========
Diluted net income $ 1.07 $ 0.78 $ 0.26
=========== =========== ===========
After effect of change in accounting principle
Basic net income $ 1.69 $ 1.17 $ 0.32
=========== =========== ===========
Diluted net income $ 1.07 $ 0.78 $ 0.27
=========== =========== ===========
F-11
5. Earnings Per Share
Basic earnings per share ("Basic EPS") is computed by dividing income
available to common stockholders by the weighted-average number of common shares
outstanding during the period. Diluted earnings per share ("Diluted EPS") gives
effect to all dilutive potential common shares outstanding during the period.
The computation of Diluted EPS does not assume conversion, exercise or
contingent exercise of securities that would have an antidilutive effect on
earnings. The following table is the reconciliation from basic to diluted shares
for the years ended March 31, 2004, 2003 and 2002.
Year Ended March 31,
2004 2003 2002
---------- ---------- ----------
Basic shares 10,710,742 10,148,991 10,137,209
Dilutive:
Options 1,381,554 940,381 449,384
Warrants 4,772,192 4,054,627 1,328,758
---------- ---------- ----------
Diluted shares 16,864,488 15,143,999 11,915,351
========== ========== ==========
At March 31, 2004, 2003 and 2002, outstanding options and warrants to
purchase 87,061, 434,066 and 2,393,833 shares of common stock, respectively, at
exercise prices ranging from $0.50 to $27.72 per share have been excluded from
the computation of diluted earnings per share as they are antidilutive.
6. Inventories
Inventories at March 31, 2004 and 2003, net of provisions for excess and
obsolete inventories, are comprised of the following:
2004 2003
------ ------
Raw materials $2,088 $2,103
Work-in-process 246 241
Finished goods 723 695
------ ------
Total inventories $3,057 $3,039
====== ======
7. Equipment
Equipment at March 31, 2004 and 2003 is comprised of the following:
2004 2003
------- -------
Production equipment $ 5,751 $ 5,572
Computer and communications equipment 2,493 2,389
Demonstration equipment 944 944
Leasehold improvements 1,907 1,907
Other equipment 137 128
------- -------
Total equipment 11,232 10,940
Less accumulated depreciation and amortization 9,827 8,789
------- -------
Equipment, net $ 1,405 $ 2,151
======= =======
F-12
8. Short-term investments
At March 31, 2004, the Company held no short-term investments.
Held-to-maturity securities at March 31, 2003 included short-term U.S. Treasury
and government agency debt securities of $660 on an amortized cost basis, with
maturity dates of less than one year. The gross unrealized gains and losses at
March 31, 2003 on held-to-maturity securities were insignificant.
9. Accounts payable and accrued expenses
Accounts payable and accrued expenses are summarized as follows at March
31, 2004 and 2003:
2004 2003
------ ------
Advertising and marketing expenses $ 103 $ 106
Inventory 435 635
Printing -- 100
Professional fees 290 40
Refunds payable 95 95
Royalties 120 82
Travel and entertainment 118 190
Other 295 220
------ ------
Accounts payable and accrued expenses $1,456 $1,468
------ ------
10. Debt
Long-term debt is summarized as follows at March 31, 2003:
2003
------
Term notes $1,503
Less current maturities 1,503
------
Secured Term Notes
The Company prepaid its secured term notes with Greystone Funding
Corporation ("Greystone") in full on June 30, 2003. In connection with the
notes, the Company had in 1999 granted the lender 650,000 warrants at an
exercise price of $0.75 expiring in December 2006. The President of the Company
acquired 97,500 of these warrants as Greystone's designee. The fair value of the
warrants amounted to $726, and is being accounted for as deferred financing
costs. The deferred cost ($150 at March 31, 2003) was charged to interest
expense during the year ended March 31, 2004. Interest expense of approximately
$135 relating to this warrants issuance was recognized for the year ended March
31, 2003. In March 2004, Greystone exercised all of these 552,500 warrants.
Former Secured Credit Facility
In December 1999 (as amended in March 2000), the Company entered into a
Loan Agreement (the "Loan Agreement") with Greystone to provide up to $7.5
million of subordinated debt in the form of a secured credit facility. Pursuant
to the Loan Agreement, and to induce Greystone to enter into said Agreement, the
Company issued to Greystone, or its designees, warrants to purchase 3,000,000
shares of the Company's Common Stock at an exercise price of $0.75 per share.
The Company also issued to Greystone or its designees warrants to purchase an
additional 2,000,000 shares at an exercise price of $0.75 per share in
connection with a $1 million drawdown under the Loan Agreement. The President of
the Company acquired 750,000 of these warrants as Greystone's designee.
F-13
The secured term notes and secured credit facility were subject to various
financial and restrictive covenants including, among others, interest coverage,
current ratio, and EBITDA. On July 5, 2001, the Company repaid all outstanding
advances under the Greystone Loan Agreement, together with all unpaid accrued
interest thereunder (aggregating $1.05 million), and concurrently terminated
said Loan Agreement. Approximately $423 representing the unamortized discount
and deferred financing costs relating to the Loan Agreement was charged to
expense in July 2001.
On July 12, 2001, the Company and Greystone entered into a termination
agreement effective as of March 31, 2001, acknowledging the repayment and
surrender of the line of credit and cancellation of additional warrants, which
had not vested, and agreeing that all the Company's obligations thereunder have
been fully satisfied. The Company and Greystone further agreed, among other
matters, that five million warrants held by Greystone and its assigns to
purchase Common Stock of the Company remained in full force and effect and that
the Registration Rights Agreement between Greystone and the Company dated as of
December 27, 1999 remained in full force and effect. In March 2004 Greystone
exercised all of these 4,250,000 warrants.
11. Income Taxes
The following table provides detail of the income tax benefit for the
years ended March 31, 2004, 2003 and 2002:
Year Ended March 31,
2004 2003 2002
------- ------- ----
Current provision
Federal $ 250 $ 95 $ --
State -- -- --
------- ------- ----
Total current provision 250 95 --
------- ------- ----
Deferred tax benefit
Federal (4,911) (4,423) --
State (1,256) (1,032) --
------- ------- ----
Total deferred tax benefit (6,167) (5,455) --
------- ------- ----
Total income tax benefit ($5,917) ($5,360) $ --
======= ======= ====
The reconciliation between the U.S. federal statutory rate and the
Company's effective tax rate is as follows:
Year Ended March 31,
2004 2003 2002
------ ------ ------
Tax benefit at federal statutory rate 34.0% 34.0% 34.0%
State income tax expense, net of
federal tax benefit 5.3% 5.3% -8.1%
Permanent differences -0.9% -1.5% 0.9%
Alternative minimum tax 2.0% 1.4% --
Research and development tax credit -- -- 2.2%
Federal and state net operating loss and credits
(used) in the current year or generated in the
year in which there is no benefit -37.0% -37.8% -29.0%
Federal and state valuation allowance reversal -54.4% -83.2% --
Other 2.5% 1.2% --
------ ------ ------
Effective tax rate -48.5% -80.6% 0.0%
====== ====== ======
Significant components of the Company's deferred tax assets (liabilities)
at March 31, 2004, 2003 and 2002 are as follows:
F-14
March 31,
---------------------------------
2004 2003 2002
-------- -------- --------
Net operating loss carryforwards $ 6,885 $ 12,484 $ 14,636
Reserves and allowances for inventory 1,155 1,238 1,257
Accounts receivable and warranties 1,966 1,566 1,862
Tax credit and carryforwards 2,016 1,581 1,421
Depreciation and other 91 80 575
Other 47 (64) 65
-------- -------- --------
12,160 16,885 19,816
Valuation allowance -- (11,355) (19,816)
-------- -------- --------
Net deferred tax asset $ 12,160 $ 5,530 $ --
======== ======== ========
During the fourth quarter of the fiscal year ended March 31, 2003, the
Company reduced its deferred tax valuation allowance by $5.5 million. During the
fourth quarter of the fiscal year ended March 31, 2004, the Company reduced its
deferred income tax valuation allowance by $6.6 million since the Company
believes that it is more likely than not that such tax benefit will be realized.
In assessing the valuation allowance, the Company has considered future taxable
income and has determined that it is more likely than not that the deferred tax
asset will be realized. The Company will have to generate future taxable income
of $17.5 million to fully utilize its net operating loss carryforward. Changes
in these circumstances, such as a decline in future taxable income, may result
in the reestablishment of a valuation allowance. During fiscal 2004, 2003 and
2002 the Company's utilization of its net operating losses resulted in a
reduction of current taxes in the amount of $4.8 million, $2.9 million and $0.6
million, respectively.
At March 31, 2004, the Company has a net operating loss carryforward for
Federal income tax purposes of $17.5 million expiring in fiscal 2019 to 2021.
While the net operating loss is currently not subject to limitation under IRC
Section 382, any future changes of ownership, as defined within IRC Section 382
may affect future utilization of such net operating loss.
Under current tax law, the utilization of the Company's tax attributes
will be restricted if an ownership change, as defined, were to occur. Section
382 of the Internal Revenue Code provides, in general, that if an "ownership
change" occurs with respect to a corporation with net operating and other loss
carryforwards, such carryforwards will be available to offset taxable income in
each taxable year after the ownership change only up to the "Section 382
Limitation" for each year (generally, the product of the fair market value of
the corporation's stock at the time of the ownership change, with certain
adjustments, and a specified long-term tax-exempt bond rate at such time). The
Company's ability to use its loss carryforwards would probably be limited in the
event of an ownership change.
12. Warranties
The Company records a liability for an estimate of costs that it expects
to incur under its basic limited warranty when product revenue is recognized.
Factors affecting the Company's warranty liability include the number of units
sold and historical and anticipated rates of claims and costs per claim. The
Company periodically assesses the adequacy of its warranty liability based on
changes in these factors.
The following table reconciles aggregate warranty liability as at March
31:
2004 2003
------- -------
Beginning balance ................ $ 56 $ 72
Warranties issued in period ...... 2,439 1,971
Warranties paid in period ........ (2,285) (1,987)
------- -------
Balance end of period ............ $ 210 $ 56
======= =======
F-15
The Company records revenues on extended warranties on a straight-line
basis over the term of the related warranty contracts (generally one-year).
Deferred revenues related to extended warranties were $2.4 and $2.3 million at
March 31, 2004 and 2003, respectively.
13. Concentration of Risks and Customer Information
The Company's future results of operations involve a number of risks and
uncertainties. Factors that could affect the Company's future operating results
and cause actual results to vary materially from expectations include, but are
not limited to, dependence on key personnel, government regulation,
manufacturing disruptions, competition, reliance on certain customers and
vendors, absence of redundant facilities, credit risk, product liability and
other liability claims, adequacy of insurance coverage and litigation.
Substantially all of the Company's sales are to domestic and foreign
dentists, doctors, and distributors of dental and medical supplies and
equipment. Financial instruments that potentially subject the Company to
concentrations of credit risks are primarily accounts receivable and cash
equivalents. The Company generally does not require collateral and the majority
of its trade receivables are unsecured. The Company is directly affected by the
financial well being of the dental and medical industries. The Company places
its cash equivalents in short-term money market instruments.
The Company currently purchases each of its primary raw materials, the
active-pixel sensor ("APS") and the charged coupled device ("CCD") semiconductor
wafers, from single suppliers. During the fourth quarter of fiscal 1998, the
Company experienced a delay in the supply flow from its CCD vendor, which
resulted in manufacturing and product shipment delays. Although there are a
number of manufacturers capable of supplying these materials, which the Company
believes could provide for its semiconductor requirements on comparable terms,
such delays could occur again.
Approximately $9.9 million of the Company's sales in fiscal 2004 and $6.2
million thereof in each of fiscal 2003 and 2002, were to foreign customers. The
majority of such foreign sales were to customers in Europe and Asia. During
2004, 2003 and 2002, sales of $21.6, $15.4 million and $9.9 million,
respectively, were made to a single customer.
On April 6, 2000, the Company entered into an agreement with Patterson
Dental Company which granted Patterson exclusive rights to distribute the
Company's dental products in the United States and Canada effective May 1, 2000.
14. Commitments and Contingencies
Employment Agreements and Termination of Employment Arrangements
The Company has employment agreements with certain executive officers. As
of March 31, 2004, minimum compensation obligations under these employment
agreements are $322 for the year ending March 31, 2005. Two employment
agreements with Company executives, the current CEO and former CEO respectively,
are included in these obligations. Both of these agreements were terminated in
June 2004 upon the resignation of the former CEO and the appointment of the
current CEO. In June 2004, the Company entered into a Consulting and
Non-Competition Agreement with its former CEO, and employment agreements with
its current CEO and with its Executive Vice-President of Sales and Marketing.
These agreements provide for aggregate cumulative payments of $2.5 million,
consisting of $724 in fiscal 2005, $932 in fiscal 2006, $741 in fiscal 2007 and
$144 in fiscal 2008. See Note 18, "Subsequent Events."
In addition, certain of the Company's agreements provide for the issuance
of common stock and/or common stock options to the executives, which generally
vest ratably over the term of the agreements (2-3 years). Additionally, certain
executives may earn bonus compensation based upon the specific terms of the
respective agreements, as defined.
F-16
Operating Leases
The Company leases its facilities under an operating lease agreement
expiring June 2007. Rent expense for the years ended March 31, 2004, 2003, and
2002 was $646, $367, and $470 respectively.
Future minimum payments on a fiscal year basis under non-cancelable
operating leases are as follows:
2005 $ 486
2006 506
2007 526
2008 137
------
$1,655
======
Product Liability
The Company is subject to the risk of product liability and other
liability claims in the event that the use of its products results in personal
injury or other claims. Although the Company has not experienced any product
liability claims to date, any such claims could have an adverse impact on the
Company. The Company maintains insurance coverage related to product liability
claims, but there can be no assurance that product or other claims will not
exceed its insurance coverage limits, or that such insurance will continue to be
maintained or to be available on commercially acceptable terms, or at all.
SEC Investigation and other
In August 1999, the Company, through its outside counsel, contacted the
Division of Enforcement of the Securities and Exchange Commission ("SEC") to
advise it of certain matters related to the Company's restatement of earnings
for interim periods of fiscal 1999. Subsequent thereto, the SEC requested the
voluntary production of certain documents and the Company provided the SEC with
the requested materials. On August 17, 2000 and April 30, 2003, the SEC served
subpoenas upon the Company, pursuant to a formal order of investigation,
requiring the production of certain documents. The Company timely provided the
SEC with the subpoenaed materials. The Company has been informed that since
January 2002 the SEC and/or the United States Attorney's Office for the Southern
District of New York have served subpoenas upon and/or contacted certain
individuals, including current and former officers and employees of the Company,
and a current Director, in connection with this matter. On June 13, 2002, the
Company was advised by counsel to David Schick, the Company's former chief
executive officer, that the United States Attorney's Office for the Southern
District of New York had notified such counsel that Mr. Schick was a target of
the United States Attorney's investigation of this matter. The Company has
cooperated with the SEC staff and U.S. Attorney's Office.
On November 14, 2003, the SEC filed a civil action in the United States
District Court for the Eastern District of New York against the Company, its
former chief executive officer, and its former vice president of sales &
marketing. The SEC complaint alleges fraud, and books and records and reporting
violations under Sections 10(b), 13(a) and 13(b)(2) of the Securities Exchange
Act and various rules promulgated thereunder in connection with the financial
statements included in the Company's reports on Form 10-Q for the quarters ended
June 30, September 30 and December 31, 1998. The SEC complaint seeks to enjoin
the Company from future violations of those provisions of the Exchange Act and
the rules thereunder, as well as disgorgement of any ill-gotten gains, which the
Company does not believe to be material in amount. With respect to the other
defendants, the complaint seeks injunctive relief, civil penalties, disgorgement
and an officer/director bar.
In September 2003, the Board of Directors appointed a Special Litigation
Committee, consisting of Messrs. Blank (Chair), Hood, Landesman and Rocca, which
has oversight responsibility and authority with respect to the SEC/U.S. Attorney
matter. The Company promptly commenced discussions with the SEC's northeast
regional office in an effort to resolve the complaint against the Company. There
can be no assurance that those discussions will continue and/or will be
successful. The Company will continue to incur significant legal fees and may
incur indemnification costs. However, the Company believes that the magnitude of
such expenditures will not adversely affect its ongoing business operations.
F-17
The Company cannot predict the potential outcome of these matters and
their impact on the Company and, therefore, has made no provision relating to
these matters in the accompanying consolidated financial statements.
Litigation
The Company may be a party to a variety of legal actions (in addition to
that referred to above), such as employment and employment
discrimination-related suits, employee benefit claims, breach of contract
actions, tort claims, shareholder suits, including securities fraud, and
intellectual property related litigation. In addition, because of the nature of
its business, the Company is subject to a variety of legal actions relating to
its business operations. Recent court decisions and legislative activity may
increase the Company's exposure for any of these types of claims. In some cases,
substantial punitive damages may be sought. The Company currently has insurance
coverage for some of these potential liabilities. Other potential liabilities,
such as those based upon the commission of fraud, may not be covered by
insurance, insurers may dispute coverage, or the amount of insurance may not be
sufficient to cover the damages awarded. In addition, certain types of damages,
such as punitive damages, may not be covered by insurance and insurance coverage
for all or certain forms of liability may become unavailable or prohibitively
expensive in the future.
15. Stock Option Plan, Stock Grants and Defined Contribution Plan
Stock Option Plan and Stock Grants
In April 1996, the Company implemented its 1996 Stock Option Plan (the
"Plan") whereby incentive and non-qualified options to purchase shares of the
Company's common stock may be granted to employees, directors and consultants.
In September 1998, the Plan was amended to increase the number of shares of
common stock issuable under the Plan from 470,400 to 1,000,000, and the Plan was
further amended in November 2000 to increase the number of shares of common
stock issuable under the Plan to 3,000,000. The Board of Directors determines
exercise and vesting periods and the exercise price of options granted under the
Plan. The Plan stipulates that the exercise price of non-qualified options
granted under the Plan must equal or exceed 85% of the fair market value of the
Company's common stock as of the date of grant of the option; however, the
Company has never granted options having an exercise price lower than the fair
market value of the underlying common stock on the date of grant. Additionally,
no option may be exercisable after ten years from the date of grant. Options
granted under the plan generally vest over a period of four years.
In 1997, the Company adopted the Directors Plan. In November 2002, the
plan was amended to increase the number of shares of Common Stock issuable to
600,000. At March 31, 2004, 2003 and 2002, a total of 488,000, 330,000 and
266,875 options to purchase common stock pursuant to the Directors Plan were
outstanding, respectively. The plan stipulates that the exercise price of
non-qualified options granted under the plan must equal or exceed 85% of the
fair market value of the Company's common stock as of the date of grant of the
option, and no option may be exercisable after ten years from the date of grant.
Options granted under the plan generally vest over a period of four years. The
Company has never granted options at less than market on the date of grant.
The fair value of options granted to employees and directors during 2004,
2003 and 2002 has been determined on the date of the respective grant using the
Black-Scholes option-pricing model based on the following weighted-average
assumptions:
2004 2003 2002
---------- ---------- ----------
Dividend yield None None None
Risk-free interest rate on date of grant 1.04%-1.29% 2.24%-3.03% 2.81%-3.56%
Forfeitures None None None
Expected life 4 years 4 years 4 years
Volatility 75% 82% 84%
Weighted average fair value per share $4.10 $1.62 $0.55
F-18
The following table summarizes information regarding stock options for
2004, 2003 and 2002:
2004 2003 2002
------------------------ ------------------------ -------------------------
Shares Weighted Shares Weighted Shares Weighted
Under Average Under Average Under Average
Option Exercise Option Exercise Option Exercise
Price Price Price
--------- --------- --------- --------- --------- ---------
Options outstanding,
beginning of year 2,077,538 $ 2.54 1,840,426 $ 2.47 1,046,807 $ 3.53
Options granted 362,997 7.41 332,862 2.69 859,739 1.31
Options exercised (292,328) 1.44 (68,100) 0.98 (1,176) 1.00
Options forfeited (23,943) 10.52 (27,650) 3.72 (64,944) 4.14
--------- --------- ---------
Options outstanding,
end of year 2,124,264 $ 3.36 2,077,538 $ 2.54 1,840,426 $ 2.47
========= ========= =========
Range of Options outstanding Weighted average remaining
exercise prices at March 31, 2004 contractual life (years)
---------------- ----------------- ------------------------
$ 0.50 to $ 1.56 1,106,980 6
$ 2.15 to $ 3.20 534,591 8
$ 4.91 to $ 7.86 388,253 4
$ 8.25 to $22.97 71,452 4
$24.75 to $27.72 22,988 4
At March 31, 2004, there are 1,475,736 options available for grant
pursuant to the Company's option plans.
Defined Contribution Plan
The Company has a defined contribution savings plan, which qualifies under
Section 401(k) of the Internal Revenue Code, for employees meeting certain
service requirements. Participants may contribute up to 15% of their gross wages
not to exceed, in any given year, a limitation set by the Internal Revenue
Service regulations. The plan provides for mandatory matching contributions to
be made by the Company to a maximum amount of 2.5% of a plan participant's
compensation. Company contributions to the plan approximated $190, $171 and
$135, in fiscal 2004, 2003 and 2002, respectively.
16. Stockholders' Equity
In February 2000, an executive was awarded 75,000 shares of the Company's
common stock, subject to a risk of forfeiture, which vested as to 25,000 shares
on each of December 31, 2000, 2001 and 2002. Upon the sale of any such vested
shares, the employee is required to pay the Company $1.32 per share sold within
six months following such sale. The Company recorded a note receivable, which is
presented as a reduction of Paid in Capital amounting to $99, relating to the
stock issuance. The charge to operations relating to this stock award is not
material to the financial statements.
In March 2004, Greystone exercised all of its outstanding warrants. In one
transaction, Greystone paid $414, to acquire 552,500 unregistered shares of
common stock. In a second transaction, Greystone exercised under the cashless
provision governing its grant of 4,250,000 warrants and received 3,975,216
unregistered shares of common stock. The market price of the Company's common
stock was $11.60 at the date of exercise.
17. Fourth quarter adjustments
During the three months ended March 31, 2004 the Company reduced legal
expenses by $0.4 million and recorded a receivable from its D&O insurance
carrier as a partial recovery of legal expense incurred in connection with the
SEC/US attorney matter. This amount was received during the first quarter of
fiscal 2005. During the three months ended March 31, 2004 the Company eliminated
its remaining reserve against deferred income taxes and recorded a benefit for
income taxes of $6.6 million.
F-19
18. Subsequent Events
In May 2004, the Company entered into a Consulting and Non-Competition
Agreement with David Schick, effective upon Mr. Schick's resignation in June
2004 as the Company's Chief Executive Officer and Chairman of the Board. The
Agreement provides for Mr. Schick to act as a consultant to the Company for a
period of three years. It also provides that during the term of the Agreement,
and for a period of two years thereafter, Mr. Schick may not compete with the
Company, solicit Company employees, customers or vendors, or disclose any of the
Company's proprietary information. Pursuant to the Agreement, Mr. Schick is to
be compensated, in full payment for the consulting services to be rendered to
the Company and for his non-competition and other covenants contained in the
Agreement, in the amount of $28,333 per month for a period of 36 months. In
addition, the Agreement provides that 66,307 unvested employee stock options
held by Mr. Schick continue to vest.
In June, 2004, the Company entered into a three-year employment agreement
with Jeffrey T. Slovin. Pursuant to the Agreement, Mr. Slovin is employed as the
Company's Chief Executive Officer and President. Mr. Slovin's annual base salary
is $325,000, $337,000 and $350,000, respectively, during each year of the
initial 3-year term of the Agreement. In addition to base salary, Mr. Slovin is
eligible to receive a yearly bonus payment based on the Company's year-over-year
Earnings-Per-Share growth, as defined in the Agreement. Pursuant to the
Agreement, Mr. Slovin was also awarded 400,000 employee stock options which vest
in equal monthly increments over a period of 48 months. Additionally, under the
Agreement, all Company stock options held by Mr. Slovin will immediately vest in
the event that the Company has a change in control or is acquired by another
company or entity, or, under certain circumstances, if Mr. Slovin is terminated
from employment without cause. In addition, if Mr. Slovin is terminated without
cause, the Agreement provides that he shall receive severance payments equal to
12 months' salary and, if applicable, a pro-rated bonus.
In June, 2004, the Company entered into a two-year employment agreement
with Michael Stone. Pursuant to the Agreement, Mr. Stone is employed as the
Company's Executive Vice President of Sales and Marketing. Mr. Stone's annual
base salary is $250,000 and $260,000, respectively, during each year of the
2-year term of the Agreement. In addition to base salary, Mr. Stone is eligible
to receive a yearly bonus payment based on the Company's year-over-year
Earnings-Per-Share growth, as defined in the Agreement. Pursuant to the
Agreement, Mr. Stone was also awarded 150,000 employee stock options which vest
in equal monthly increments over a period of 48 months. Additionally, under the
Agreement, all Company stock options held by Mr. Stone will immediately vest in
the event that the Company has a change in control or is acquired by another
company or entity, or, under certain circumstances, if Mr. Stone is terminated
from employment without cause. In addition, if Mr. Stone is terminated without
cause, the Agreement provides that he shall receive severance payments equal to
12 months' salary and, if applicable, a pro-rated bonus.
See Note 14, "Commitments and Contingencies - Employment Agreements and
Termination of Employment Arrangements."
19. Unaudited selected quarterly financial data
The following is a summary of the Company's unaudited quarterly operating
results for the years ended March 31, 2004 and 2003:
F-20
Mar 31, Dec 31, Sep 30, Jun 30,
2004 2003 2003 2003
----------- ----------- ----------- -----------
Statement of Operations Data:
Revenue, net $ 10,092 $ 12,124 $ 8,501 $ 8,676
Total cost of sales 3,179 3,063 2,624 2,629
----------- ----------- ----------- -----------
Gross profit 6,913 9,061 5,877 6,047
----------- ----------- ----------- -----------
Gross profit margin 68.5% 74.7% 69.1% 69.7%
Operating expense:
Selling and marketing 1,613 1,655 1,415 1,435
General and administrative 1,475 1,725 1,541 1,655
Research and development 793 827 839 842
----------- ----------- ----------- -----------
Operating expense 3,881 4,207 3,795 3,932
----------- ----------- ----------- -----------
Income from operations 3,032 4,854 2,082 2,115
----------- ----------- ----------- -----------
Net income $ 9,009 $ 4,854 $ 2,267 $ 1,979
=========== =========== =========== ===========
Earnings per share:
Basic income $ 0.76 $ 0.47 $ 0.22 $ 0.19
=========== =========== =========== ===========
Diluted income $ 0.53 $ 0.29 $ 0.13 $ 0.12
=========== =========== =========== ===========
Weighted average common
shares outstanding (basic) 11,836,330 10,407,356 10,365,939 10,229,697
=========== =========== =========== ===========
Weighted average common
shares outstanding (diluted) 17,129,496 16,879,982 16,911,580 16,536,892
=========== =========== =========== ===========
Mar 31, Dec 31, Sep 30, Jun 30,
2003 2002 2002 2002
----------- ----------- ----------- -----------
Statement of Operations Data:
Revenue, net $ 7,347 $ 8,816 $ 6,750 $ 6,904
Total cost of sales 2,209 2,653 2,474 2,292
----------- ----------- ----------- -----------
Gross profit 5,138 6,163 4,276 4,612
----------- ----------- ----------- -----------
Gross profit margin 69.9% 69.9% 63.3% 66.8%
Operating expense:
Selling and marketing 1,654 1,482 1,334 1,441
General and administrative 1,492 1,179 1,268 1,102
Research and development 689 663 580 666
----------- ----------- ----------- -----------
Operating expense 3,835 3,324 3,182 3,209
----------- ----------- ----------- -----------
Income from operations 1,303 2,839 1,094 1,403
----------- ----------- ----------- -----------
Net income $ 6,676 $ 2,805 $ 1,008 $ 1,336
=========== =========== =========== ===========
Earnings per share:
Basic income $ 0.66 $ 0.28 $ 0.10 $ 0.13
=========== =========== =========== ===========
Diluted income $ 0.42 $ 0.19 $ 0.07 $ 0.09
=========== =========== =========== ===========
Weighted average common
shares outstanding (basic) 10,170,782 10,154,059 10,147,537 10,138,900
=========== =========== =========== ===========
Weighted average common
shares outstanding (diluted) 15,868,163 14,957,659 14,465,750 15,212,574
=========== =========== =========== ===========
F-21
Schedule II
Schick Technologies, Inc. and Subsidiary
Valuation and Qualifying Accounts (in thousands)
Additions
---------
Balance Charged Charged Balance
at to to at
Beginning Cost and Other End of
Of Period Expenses Accounts Deductions Period
--------- -------- -------- ---------- ------
ALLOWANCE FOR DOUBTFUL
ACCOUNTS
For the year ended March 31, 2004 $ 42 $ 105 $ 9(a) $ 138
For the year ended March 31, 2003 717 -- 675(a) 42
For the year ended March 31, 2002 1,818 1,008(a) 717
93(b)
RESERVE FOR OBSOLETE/SLOW
MOVING INVENTORY
For the year ended March 31, 2004 $ 2,837 $ 185 $ 189(c) $ 2,833
For the year ended March 31, 2003 2,899 259 321(c) 2,837
For the year ended March 31, 2002 3,195 292 588(c) 2,899
VALUATION ALLOWANCE--
DEFERRED TAX ASSET
For the year ended March 31, 2004 $11,355 $ 6,567(d) $ --
4,788(e)
For the year ended March 31, 2003 19,816 5,805(d) 11,355
2,656(e)
For the year ended March 31, 2002 21,302 1,486(e) 19,816
PROVISION FOR WARRANTY
OBLIGATIONS
For the year ended March 31, 2004 $ 56 $ 2,439 $ 2,285(f) $ 210
For the year ended March 31, 2003 72 1,971 1,987(f) 56
For the year ended March 31, 2002 141 2,761 2,830(f) 72
(a) Accounts receivable written off
(b) Accounts receivable recovered
(c) Inventory disposed of
(d) Reduction of valuation allowance and reserve adjustment
(e) NOL used in year
(f) Reduction of reserve
F-22
(a) Documents filed as a part of this Report
(1) Consolidated Financial Statements filed as part of this Report:
Index to Consolidated Financial Statements F-1
Report of Independent Registered Public Accounting Firm F-2
Consolidated Balance Sheets at March 31, 2004 and 2003 F-3
Consolidated Statements of Operations for the years ended
March 31, 2004, 2003 and 2002 F-4
Consolidated Statements of Changes in Stockholders'
Equity for the years ended March 31, 2004, 2003 and 2002 F-5
Consolidated Statements of Cash Flows for the years ended
March 31, 2004, 2003 and 2002 F-6
Notes to Consolidated Financial Statements F-7
(2) Financial statement schedules filed as part of this Report
Schedule II Valuation and Qualifying Accounts F-22
Schedules other than that mentioned above are omitted because the
conditions requiring their filing do not exist, or because the information is
provided in the financial statements filed herewith, including the notes
thereto.
(b) Reports on Form 8-K
1. A Form 8-K was filed on February 9, 2004 and reported on the
Company's press release, which announced its third quarter conference call to
report the Company's financial results for the third quarter of fiscal year
2004, in Item 7, "Financial Statements, Pro Forma Financial Information and
Exhibits," of said Form 8-K.
2. A Form 8-K was filed on February 11, 2004 and reported on the
Company's press release, which announced its financial results for the third
quarter of fiscal year 2004, in Item 12, "Results of Operations and Financial
Condition," of said Form 8-K.
(c) The following Exhibits are included in this report:
36
Filed herewith or
Exhibit incorporated
No. Item Title by Reference
--- ---------- ------------
3.1 Amended and Restated Certificate of Incorporation of the Company
(incorporated by reference to Exhibit 3.1 to the Company's
Registration Statement on Form S-1, File No. 333-33731, filed on
June 30, 1997) *
3.2 Bylaws of the Company, as amended (incorporated by reference to
Exhibit 3.2 to the Company's Annual Report on Form 10-K, filed on
July 13, 2001) *
4.1 Form of Common Stock certificate of the Company (incorporated by
reference to Exhibit 4.1 to the Company's Registration Statement on
Form S-1, File No. 333-33731, filed on June 30, 1997) *
4.2 Form of private-placement Warrant of the Company (incorporated by
reference to Exhibit 4.2 to the Company's Registration Statement on
Form S-1, File No. 333-33731, filed on June 30, 1997) *
4.3 Agreement and Plan of Merger, dated as of May 15, 1997, among Schick
Technologies, Inc., a New York corporation, Schick Technologies,
Inc., a Delaware corporation and STI Acquisition Corp, a Delaware
corporation (incorporated by reference to Exhibit 4.3 to the
Company's Registration Statement on Form S-1, File No. 333-33731,
filed on June 30, 1997) *
10.1 1996 Employee Stock Option Plan, as amended (incorporated by
reference to Exhibit 10.1 to the Company's Annual Report on Form
10-K, filed on July 13, 2001) *
10.2 1997 Stock Option Plan for Non-Employee Directors, as amended
(incorporated by reference to Exhibit 10.2 to the Company's Annual
Report on Form 10-K, filed on June 18, 2003) *
10.3 Form of Non-Disclosure, Non- Solicitation, Non-Competition and
Inventions Agreements between Schick Technologies, Inc. and Named
Executives of Schick Technologies, Inc. (incorporated by reference
to Exhibit 10.3 to the Company's Registration Statement on Form S-1,
File No. 333-33731, filed on June 30, 1997) *
37
Exhibit
No. Item Title
--- ----------
10.4 Service and License Agreement between Photobit, LLC and Schick
Technologies, Inc. dated as of June 24, 1996 (incorporated by
reference to Exhibit 10.5 to the Company's Registration Statement on
Form S-1, File No. 333-33731, filed on June 30, 1997) *
10.5 Secured Promissory Note between Schick Technologies, Inc. and DVI
Financial Services, Inc., dated as of January 25, 1999 (incorporated
by reference to Exhibit 10.10 to the Company's Annual Report on Form
10-K, filed on March 21, 2000) *
10.6 Allonge to Secured Promissory Note by and between Schick
Technologies, Inc. and DVI Financial Services, Inc., dated as of
March 4, 1999 (incorporated by reference to Exhibit 10.11 to the
Company's Annual Report on Form 10-K, filed on March 21, 2000) *
10.7 Security Agreement between Schick Technologies, Inc. and DVI
Affiliated Capital, dated January 25, 1999 (incorporated by
reference to Exhibit 10.13 to the Company's Annual Report on Form
10-K, filed on March 21, 2000) *
10.8 Employment Agreement between Schick Technologies, Inc. and David
Schick, dated February 29, 2000 (incorporated by reference to
Exhibit 10.15 to the Company's Annual Report on Form 10-K, filed on
March 21, 2000) *
10.9 Employment Letter Agreement between Schick Technologies, Inc. and
Zvi Raskin, dated February 6, 2000 (incorporated by reference to
Exhibit 10.16 to the Company's Annual Report on Form 10-K, filed on
March 21, 2000) *
10.10 Employment Letter Agreement between Schick Technologies, Inc. and
Michael Stone, dated January 12, 2000 (incorporated by reference to
Exhibit 10.17 to the Company's Annual Report on Form 10-K, filed on
March 21, 2000) *
10.11 Employment Letter Agreement between Schick Technologies, Inc. and
William F. Rogers, dated December 31, 1999 (incorporated by
reference to Exhibit 10.18 to the Company's Annual Report on Form
10-K, filed on March 21, 2000) *
10.12 Separation, Severance and General Release Agreement between Schick
Technologies, Inc. and Fred Levine, dated August 27, 1999
(incorporated by reference to Exhibit 10.19 to the Company's Annual
Report on Form 10-K, filed on March 21, 2000) *
10.13 Separation, Severance and General Release Agreement between Schick
Technologies, Inc. and Avi Itzhakov, dated August 20, 1999
(incorporated by reference to Exhibit 10.20 to the Company's Annual
Report on Form 10-K, filed on March 21, 2000) *
10.14 Loan Agreement, dated December 27, 1999, by and between Schick
Technologies, Inc., a Delaware corporation, Schick Technologies,
Inc., a New York corporation, and Greystone Funding Corporation, a
Virginia corporation ("Greystone") (incorporated by reference to
Exhibit 1 to the Company's Report on Form 8-K, filed on January 11,
2000) *
10.15 Stockholders' Agreement, dated December 27, 1999, by and between
Schick Technologies, Inc., a Delaware corporation, David B. Schick,
Allen Schick and Greystone (incorporated by reference to Exhibit 2
to the Company's Report on Form 8-K, filed on January 11, 2000) *
38
Exhibit
No. Item Title
--- ----------
10.16 Stock Purchase Agreement, dated December 27, 1999, by and between
Schick Technologies, Inc., a Delaware Corporation, and Greystone
(incorporated by reference to Exhibit 3 to the Company's Report on
Form 8-K, filed on January 11, 2000) *
10.17 Form of Warrant Certificate Issued to Greystone to Purchase Shares
of Common Stock of Schick Technologies, Inc., a Delaware Corporation
(incorporated by reference to Exhibit 4 to the Company's Report on
Form 8-K, filed on January 11, 2000) *
10.18 Amended and Restated Loan Agreement, dated March 17, 2000 and made
effective as of December 27, 1999, by and between Schick
Technologies, Inc., a Delaware corporation, Schick Technologies,
Inc., a New York corporation, and Greystone (incorporated by
reference to Exhibit 10.25 to the Company's Quarterly Report on Form
10-Q, filed on March 24, 2000) *
10.19 Agreement to Rescind Stock Purchase, dated March 17, 2000 and made
effective as of December 27, 1999, by and between Greystone and
Schick Technologies, Inc., a Delaware corporation (incorporated by
reference to Exhibit 10.26 to the Company's Annual Report on Form
10-K, filed on June 29, 2000) *
10.20 Registration Rights Agreement between Schick Technologies, Inc. and
Greystone, dated as of December 27, 1999 (incorporated by reference
to Exhibit 10.27 to the Company's Annual Report on Form 10-K, filed
on June 29, 2000) *
10.21 Second Amended and Restated Secured Promissory Note between Schick
Technologies, Inc. and DVI Financial Services, Inc., in the
principal amount of $5,000,000, dated as of March 15, 2000
(incorporated by reference to Exhibit 10.28 to the Company's Annual
Report on Form 10-K, filed on June 29, 2000) *
10.22 Second Amended and Restated Secured Promissory Note between Schick
Technologies, Inc. and DVI Financial Services, Inc., in the
principal amount of $1,596,189, dated as of March 15, 2000
(incorporated by reference to Exhibit 10.29 to the Company's Annual
Report on Form 10-K, filed on June 29, 2000) *
10.23 Security Agreement between Schick Technologies, Inc. and DVI
Financial Services, Inc., dated as of March 15, 2000 (incorporated
by reference to Exhibit 10.30 to the Company's Annual Report on Form
10-K, filed on June 29, 2000) *
10.24 Amended and Restated Security Agreement between Schick Technologies,
Inc. and DVI Financial Services, Inc., dated as of March 15, 2000
(incorporated by reference to Exhibit 10.31 to the Company's Annual
Report on Form 10-K, filed on June 29, 2000) *
10.25 Form of Warrant Certificate Issued to DVI Financial Services, Inc.
to Purchase Shares of Schick Technologies, Inc. (incorporated by
reference to Exhibit 10.32 to the Company's Annual Report on Form
10-K, filed on June 29, 2000) *
10.26 Registration Rights Agreement between Schick Technologies, Inc. and
DVI Financial Services, Inc., dated as of March 15, 2000
(incorporated by reference to Exhibit 10.33 to the Company's Annual
Report on Form 10-K, filed on June 29, 2000) *
10.27 Distributorship Agreement, dated April 6, 2000, by and between
Schick Technologies, Inc. and Patterson Dental Company (incorporated
by reference to Exhibit 10.34 to the Company's Annual Report on Form
10-K, filed on June 29, 2000) *
39
Exhibit
No. Item Title
--- ----------
10.28 Termination Agreement between Greystone and Schick Technologies,
Inc. entered into as of March 30, 2001 (incorporated by reference to
Exhibit 10.35 to the Company's Annual Report on Form 10-K, filed on
July 13, 2001) *
10.29 Employment Agreement between Schick Technologies, Inc. and Jeffrey
T. Slovin, dated November 9, 2001 (incorporated by reference to
Exhibit 10.36 to the Company's Annual Report on Form 10-K, filed on
June 17, 2002) *
10.30 Employment Agreement between Schick Technologies, Inc. and David
Schick, dated December 20, 2001 (incorporated by reference to
Exhibit 10.37 to the Company's Annual Report on Form 10-K, filed on
June 17, 2002) *
10.31 Employment Agreement between Schick Technologies, Inc. and Michael
Stone, dated as of January 14, 2002 (incorporated by reference to
Exhibit 10.38 to the Company's Annual Report on Form 10-K, filed on
June 17, 2002) *
10.32 Letter Agreement between Schick Technologies, Inc. and David Schick,
dated March 4, 2002, amending, in part, the Employment Agreement
between Schick Technologies, Inc. and David Schick, dated December
20, 2001 (incorporated by reference to Exhibit 10.39 to the
Company's Annual Report on Form 10-K, filed on June 17, 2002) *
10.33 Consulting and Non-Competition Agreement between Schick
Technologies, Inc. and David B. Schick, dated May 7, 2004 +
10.34 Employment Agreement between Schick Technologies, Inc. and Jeffrey
T. Slovin, dated June 9, 2004 +
10.35 Employment Agreement between Schick Technologies, Inc. and Michael
Stone, dated June 15, 2004 +
14.1 Code of Ethics +
21.1 List of Subsidiaries of Schick Technologies, Inc. +
23.1 Consent of Independent Registered Public Accounting Firm +
24.1 Powers of Attorney (included on signature page of this Report) +
31.1 Certification of Principal Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 +
31.2 Certification of Principal Financial Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 +
32.1 Certification of Principal Executive Officer pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 +
32.2 Certification of Principal Financial Officer pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 +
99.1 Cautionary Statement +
* Previously filed; incorporated herein by reference
+ Filed herewith
40
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Long
Island City, State of New York, on June 23, 2004.
SCHICK TECHNOLOGIES, INC.
By: /s/ Jeffrey T. Slovin
----------------------------
Jeffrey T. Slovin
Chief Executive Officer and
President
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report
has been signed below by the following persons on behalf of the registrant and
in the capacities indicated on June 23, 2004.
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Jeffrey T. Slovin and Zvi N. Raskin (with full
power to act alone), as his true and lawful attorneys-in-fact and agents, with
full powers of substitution and resubstitution, for him in his name, place and
stead to sign an Annual Report on Form 10-K of Schick Technologies, Inc, and to
file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents full power and authority to do and perform each and
every act and thing requisite or necessary to be done in and about the premises,
as fully to all intents and purposes as he or she might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and agents, or
their substitute or substitutes, lawfully do or cause to be done by virtue
hereof.
Signature Title
--------- -----
/s/ Jeffrey T. Slovin Chief Executive Officer, President and
----------------------- Director
Jeffrey T. Slovin
/s/ Ronald Rosner Director of Finance and Administration
----------------------- (Principal financial and accounting officer)
Ronald Rosner
/s/ William K. Hood Chairman of the Board and Director
-----------------------
William K. Hood
/s/ Allen Schick Director
-----------------------
Allen Schick
/s/ Euval Barrekette Director
-----------------------
Euval Barrekette
/s/ Jonathan Blank Director
-----------------------
Jonathan Blank
/s/ Curtis M. Rocca III Director
-----------------------
Curtis M. Rocca III
/s/ Uri Landesman Director
-----------------------
Uri Landesman
41